[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 84 of about 84
1. Takagi A, Kojima S, Watanabe T, Ida M, Kawagoe S: Rippling muscle syndrome preceding malignant lymphoma. Intern Med; 2002 Feb;41(2):147-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rippling muscle syndrome preceding malignant lymphoma.
  • Three years later, malignant lymphoma (histologically, lymphoplasmacytoid lymphoma) was found in the sacrum.
  • The lymphoma subsided with treatment by vincristine, cyclophosphamide, doxorubicin and prednisolone.
  • The rippling phenomenon also responded to the treatment.
  • The present rippling muscle syndrome might be of a paraneoplastic or autoimmune origin related to lymphoma, although the evidence seemed indirect.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Muscle Contraction. Neuromuscular Diseases / diagnosis. Paraneoplastic Syndromes / diagnosis. Sacrum / pathology. Spinal Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Electromyography. Hypertrophy. Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Muscle Fibers, Skeletal / pathology. Muscle, Skeletal / pathology. Prednisolone / administration & dosage. Reflex, Abnormal. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Neuromuscular Disorders.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868604.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


2. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV: Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol; 2009 Dec;147(5):677-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenström macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab.
  • We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%).
  • Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunoglobulin M / blood. Male. Middle Aged. Rituximab. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 2001 May-Jun;24(3):272-9 [11394506.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):121-6 [12720120.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):127-31 [12720121.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):220-5 [12720140.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2047-55 [15370249.001]
  • [Cites] Blood. 2009 Jan 22;113(4):793-6 [18931340.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):132-8 [15598950.001]
  • [Cites] Blood. 2006 May 1;107(9):3442-6 [16410453.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Mar;6(5):380-3 [16640813.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):700-20 [17672883.001]
  • [Cites] Ann Hematol. 2009 Jan;88(1):51-7 [18665360.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2057-61 [15370250.001]
  • (PMID = 19751237.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00005609
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013650; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / R01 CA111345; United States / NCI NIH HHS / CA / U10 CA049883; United States / NCI NIH HHS / CA / P30 CA082709; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / U10 CA023318
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoglobulin M; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS429325; NLM/ PMC3548235
  •  go-up   go-down


3. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood; 2007 Jun 1;109(11):4964-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
  • Waldenström macroglobulinemia (WM) is an incurable lymphoplasmacytic lymphoma with limited options of therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Enzyme Inhibitors / pharmacology. Indoles / pharmacology. Protein Kinase C / antagonists & inhibitors. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Antigens, CD19 / biosynthesis. Biopsy. Dose-Response Relationship, Drug. Enzyme Activation. Humans. In Vitro Techniques. Inhibitory Concentration 50. Leukocytes, Mononuclear / immunology. Oligonucleotide Array Sequence Analysis. Protein Kinase C beta. Time Factors

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284528.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Indoles; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta; UC96G28EQF / enzastaurin
  •  go-up   go-down


Advertisement
4. Auw-Haedrich C, Coupland SE, Kapp A, Schmitt-Gräff A, Buchen R, Witschel H: Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma. Br J Ophthalmol; 2001 Jan;85(1):63-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term outcome of ocular adnexal lymphoma subtyped according to the REAL classification. Revised European and American Lymphoma.
  • AIM: To classify ocular adnexal lymphomas according to the Revised European and American Lymphoma (REAL) classification and to determine any correlation between clinical features or histomorphological variables with the patients' outcome.
  • METHODS: Conventional and immunohistology were performed on representative sections of 53 specimens of 46 patients with ocular adnexal lymphoma.
  • The Student's t test and log rank test were used for statistical analysis.
  • Almost all specimens represented B cell non-Hodgkin's lymphomas: extranodal marginal zone lymphoma (EMZL) (n=38), diffuse large cell B cell lymphoma (n=8), lymphoplasmocytic lymphoma/immunocytoma (n=2), mantle cell lymphoma (n=2), follicle centre lymphoma (n=1), and plasmacytoma (n=1).
  • One case of a secondary anaplastic large cell lymphoma of T cell type (T-ALCL) was diagnosed.
  • A variety of therapeutic regimens was administered, the main form of treatment being radiotherapy.
  • The average follow up time was 85 months.
  • Complete remission was achieved in 24 patients (10 after excision alone, eight after radiotherapy alone, three after combined excision and radiotherapy, one after chemotherapy alone, and two after combined radiotherapy and chemotherapy).
  • 12 patients died of causes related to lymphoma; in one patient the cause of death was unknown.
  • The stage at presentation, as well as the lymphoma malignancy category, had a significant correlation with the final course of the disease (p=0.0001 and p=0.03, respectively).
  • CONCLUSION: 67% of patients with ocular adnexal lymphoma had EMZL.
  • Primary diffuse large cell B cell lymphoma of the ocular adnexa requires at least similar therapeutic measures and regular intensive follow up.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1996 Jan;105(1):31-7 [8561085.001]
  • [Cites] J Pathol. 1994 Aug;173(4):371-9 [7965396.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1869-70 [5121698.001]
  • [Cites] Ophthalmology. 1979 May;86(5):948-66 [545222.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):576-89 [6994870.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Ann Ophthalmol. 1984 Nov;16(11):1046-55 [6549113.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2121-9 [2804350.001]
  • [Cites] Trans Am Ophthalmol Soc. 1989;87:420-42; discussion 442-4 [2562543.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Pathol Res Pract. 1991 Jan;187(1):78-84 [2027825.001]
  • [Cites] Mayo Clin Proc. 1993 Oct;68(10):1003-10 [8412350.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • (PMID = 11133714.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1723704
  •  go-up   go-down


5. German Low Grade Lymphoma Study Group, Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol; 2003 Feb;30(1S2):16-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
  • Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma.
  • In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies.
  • Therefore, randomized phase III studies have been undertaken to determine whether rituximab plus chemotherapy can significantly improve outcomes compared with conventional chemotherapy in indolent non-Hodgkin's lymphoma.
  • A study by the German Low-Grade Study Group has evaluated rituximab in combination with FCM (fludarabine/cyclophosphamide/mitoxantrone) in a randomized setting versus FCM alone in patients with relapsed or refractory follicular, mantle cell, or lymphoplasmacytic lymphoma.
  • Superiority of rituximab plus FCM was seen in both follicular lymphoma (n = 53; ORR 92% v 75%; CR 40% v 21%) and, most strikingly, in mantle cell lymphoma (n = 38; ORR 65% v 33; CR 35% v 0%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2003 Elsevier Science (USA). All rights reserved.
  • (PMID = 28140216.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL: Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res; 2006 Dec 1;12(23):7174-9
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
  • The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed.
  • RESULTS: The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52.
  • In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52.
  • In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified.
  • Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression.
  • CONCLUSION: In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Glycoproteins / biosynthesis. Leukemia, Myeloid. Lymphoma, B-Cell. Lymphoma, T-Cell. Lymphoproliferative Disorders
  • [MeSH-minor] Acute Disease. Antibodies, Monoclonal, Humanized. Humans. Immunohistochemistry. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145843.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  •  go-up   go-down


7. Berentsen S, Beiske K, Tjønnfjord GE: Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology; 2007 Oct;12(5):361-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.
  • The results of therapy with corticosteroids, alkylating agents and interferon-alpha have been poor.
  • By flowcytometric and immunohistochemical assessments, a monoclonal CD20+kappa+B-lymphocyte population has been demonstrated in the bone marrow of 90% of the patients, and lymphoplasmacytic lymphoma is a frequent finding.
  • Novel attempts at treatment for primary CAD have mostly been directed against the clonal B-lymphocytes.
  • Phase 2 studies have shown that therapy with the chimeric anti-CD20 antibody rituximab produced partial response rates of more than 50% and occasional complete responses.
  • In this review, we discuss the clinical and pathogenetic features of primary CAD, emphasizing the more recent data on its close association with clonal lymphoproliferative bone marrow disorders and implications for therapy.
  • We also review the management and outline some perspectives on new therapy modalities.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Alkylating Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes / pathology. Bone Marrow / pathology. Clone Cells / pathology. Cryoglobulins / analysis. Cryoglobulins / immunology. Humans. Immunotherapy. Interferon-alpha / therapeutic use. Lymphoproliferative Disorders / complications. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / pathology. Rituximab

  • Genetic Alliance. consumer health - Cold Agglutinin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2002 Apr;69(4):258-71 [11921020.001]
  • [Cites] Rev Med Interne. 2002 Nov;23(11):901-9 [12481390.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):697-703 [12704346.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):239-42 [12720144.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):243-7 [12720145.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):318-24 [12720161.001]
  • [Cites] Rev Med Interne. 2003 Aug;24(8):501-4 [12888170.001]
  • [Cites] Scand J Immunol. 2004 Jan;59(1):103-8 [14723628.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2925-8 [15070665.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):66-9 [15193444.001]
  • [Cites] Am J Hematol. 1996 Dec;53(4):279-80 [8948674.001]
  • [Cites] APMIS. 1997 May;105(5):354-62 [9201236.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Transfusion. 1997 Nov-Dec;37(11-12):1111-6 [9426632.001]
  • [Cites] Eur J Haematol. 1998 Feb;60(2):93-100 [9508349.001]
  • [Cites] Ann Hematol. 1998 May;76(5):201-4 [9671133.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):4091-7 [9780180.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3490-1 [9787200.001]
  • [Cites] Eur J Haematol. 1999 Oct;63(4):259-66 [10530415.001]
  • [Cites] Acta Med Scand. 1954;148(4):299-308 [13157944.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Transfus Sci. 2000 Feb-Apr;22(1-2):113-9 [10771399.001]
  • [Cites] Eur J Haematol. 2000 Jul;65(1):88-90 [10914950.001]
  • [Cites] Cytokines Cell Mol Ther. 2000 Jun;6(2):81-7 [11108573.001]
  • [Cites] Scand J Immunol. 2001 Jul-Aug;54(1-2):239-42 [11439172.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2134-42 [14764523.001]
  • [Cites] Scand J Haematol. 1965;2(3):259-66 [4158055.001]
  • [Cites] Semin Hematol. 1966 Jan;3(1):27-47 [5323366.001]
  • [Cites] Scand J Clin Lab Invest. 1966;18(1):1-15 [5918670.001]
  • [Cites] Scand J Haematol. 1969;6(6):416-26 [4984643.001]
  • [Cites] J Clin Invest. 1976 Oct;58(4):942-9 [965497.001]
  • [Cites] Br J Haematol. 1957 Jul;3(3):262-75 [13460195.001]
  • [Cites] J Exp Med. 1957 Nov 1;106(5):689-702 [13475624.001]
  • [Cites] Acta Med Scand. 1961 Dec;170:725-9 [14452388.001]
  • [Cites] Scand J Haematol. 1964;1:223-37 [14214902.001]
  • [Cites] Ann Intern Med. 1956 Feb;44(2):221-40 [13292836.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:48-62 [15561676.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):474-81 [15659493.001]
  • [Cites] Clin Lymphoma. 2005 Mar;5(4):261-4 [15794861.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):253-60 [16321854.001]
  • [Cites] Clin Lab Haematol. 2006 Feb;28(1):57-9 [16430461.001]
  • [Cites] Haematologica. 2006 Feb;91(2):176-83 [16461301.001]
  • [Cites] Haematologica. 2006 Apr;91(4):439-41 [16585009.001]
  • [Cites] Haematologica. 2006 Apr;91(4):460-6 [16585012.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1233-43 [16990386.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2520-30 [16794250.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:19-23 [17124034.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 6:S27-33 [9010576.001]
  • [Cites] Am J Hematol. 1977;2(3):259-70 [596370.001]
  • [Cites] Cancer. 1978 Oct;42(4):1826-33 [101298.001]
  • [Cites] Blood. 1980 Sep;56(3):409-16 [7407408.001]
  • [Cites] Blood. 1981 Jan;57(1):189-91 [7448411.001]
  • [Cites] Br Med J (Clin Res Ed). 1981 Jun 20;282(6281):2023-7 [6788179.001]
  • [Cites] Am J Med. 1982 Jun;72(6):915-22 [6807086.001]
  • [Cites] Blood. 1986 Jun;67(6):1705-9 [3486685.001]
  • [Cites] Acta Haematol. 1988;79(1):20-5 [3124457.001]
  • [Cites] Ann Intern Med. 1989 Aug 1;111(3):255-6 [2502059.001]
  • [Cites] Eur J Immunol. 1990 Sep;20(9):1971-9 [2120070.001]
  • [Cites] Semin Hematol. 1991 Jan;28(1):66-77 [1708169.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2337-44 [1382098.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2821-33 [8254037.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):242-3 [7957810.001]
  • [Cites] Tidsskr Nor Laegeforen. 1995 Feb 10;115(4):473-5 [7871504.001]
  • [Cites] Infusionsther Transfusionsmed. 1994 Dec;21(6):405-9 [7873919.001]
  • [Cites] Infusionsther Transfusionsmed. 1994 Dec;21(6):410-5 [7873920.001]
  • [Cites] Br J Haematol. 1996 Jan;92(1):71-6 [8562414.001]
  • [Cites] N Engl J Med. 1996 Feb 15;334(7):437 [8552146.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3383-9 [11719378.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):79-83 [11722415.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Haematologica. 2002 Feb;87(2):113-4 [11836158.001]
  • (PMID = 17891600.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Alkylating Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cryoglobulins; 0 / Interferon-alpha; 0 / cold agglutinins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 88
  • [Other-IDs] NLM/ PMC2409172
  •  go-up   go-down


8. Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, Bahlis NJ, Snell MR, Dowlati A, Cooper BW: Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol; 2009 Oct;147(1):89-96
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
  • Based on the hypothesis that bortezomib may potentiate fludarabine activity by inhibiting DNA repair, we designed a phase I trial using this combination with rituximab in patients with relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma subtypes included 12 patients with follicular lymphoma, four with marginal zone lymphoma, three with lymphoplasmacytic lymphoma, three with mantle cell lymphoma and two with small lymphocytic/chronic lymphocytic leukaemia.
  • Clinical responses were observed in 11 patients, five of whom were refractory to their most recent treatment regimen.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]
  • [Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2615-22 [10363983.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):712-9 [15613695.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):407-17 [15813915.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2902-11 [16675587.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] J Biol Chem. 2007 Jun 15;282(24):17330-4 [17478428.001]
  • [Cites] Cancer Invest. 2007 Dec;25(8):766-75 [18058474.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Leukemia. 2008 Jan;22(1):179-85 [17898787.001]
  • [Cites] Blood. 2008 May 1;111(9):4681-9 [18227347.001]
  • [Cites] Med Oncol. 2008;25(4):374-9 [18278570.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):511-8 [19075279.001]
  • [Cites] J Peripher Nerv Syst. 2008 Dec;13(4):275-82 [19192067.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5023-30 [19770386.001]
  • [CommentIn] Br J Haematol. 2010 Mar;148(5):810-2 [19919649.001]
  • (PMID = 19656151.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA043703-19; United States / NCI NIH HHS / CA / U01 CA062502-15; United States / NCI NIH HHS / CA / CA043703-19; United States / NCI NIH HHS / CA / U01 CA062502; United States / NCRR NIH HHS / RR / M01RR00080; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA62502; None / None / / U01 CA062502-15; United States / NCI NIH HHS / CA / P30 CA43703; United States / NCRR NIH HHS / RR / M01 RR000080
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS174604; NLM/ PMC2827854
  •  go-up   go-down


9. Aerts JG, de Jongh F, van Iperen CE, Lam KH, Hoogsteden HC, van Meerbeeck JP: [Pulmonary problems associated with lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia)]. Ned Tijdschr Geneeskd; 2002 May 25;146(21):999-1002
MedlinePlus Health Information. consumer health - Breathing Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary problems associated with lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia)].
  • [Transliterated title] Longklachten bij lymfoplasmocytair lymfoom (ziekte van Waldenström).
  • A 62-year-old man, known for some years due to lymphoplasmacytic lymphoma, was admitted with progressive dyspnoea.
  • Upon cytological examination, a highly increased level of kappa-positive B-lymphoid cells was found, as is seen in cases of lymphoplasmacytic lymphoma (Waldenström's macroglobulinaemia).
  • Following chemotherapy, the dyspnoea lessened and the pulmonary infiltrates disappeared.
  • In patients with a lymphoproliferative disorder, pulmonary infiltrates due to infection are found relatively frequently.
  • This case report highlights a rare complication of the disease, namely pulmonary infiltrates caused by infiltration of lymphoplasmacytic cells, emphasising the importance of cytological examination of broncho-alveolar lavage fluid.
  • [MeSH-major] Dyspnea / etiology. Waldenstrom Macroglobulinemia / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2002 Aug 31;146(35):1664 [12233165.001]
  • (PMID = 12058634.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Veidt RG, Ansari-Lari A, Brodsky RA: Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and lymphoplasmacytic lymphoma. Leuk Lymphoma; 2005 Aug;46(8):1243-6
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe aplastic anemia associated with paroxysmal nocturnal hemoglobinuria and lymphoplasmacytic lymphoma.
  • An unusual case of aplastic anemia presenting in association with lymphoplasmacytic lymphoma and paroxysmal nocturnal hemoglobinuria is discussed.
  • An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological clonal disorders.
  • [MeSH-major] Anemia, Aplastic / complications. Bone Marrow Neoplasms / complications. Hemoglobinuria, Paroxysmal / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Aged. Antilymphocyte Serum / administration & dosage. Antilymphocyte Serum / therapeutic use. Cyclosporine / administration & dosage. Cyclosporine / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Fatal Outcome. Humans. Male. Time Factors


11. Ustun C, Savage N, Manaloor E, Kunavarapu C, Jillella A: Amyloidosis, Evans syndrome and management options of lymphoplasmacytic lymphoma. Amyloid; 2009 Mar;16(1):42-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amyloidosis, Evans syndrome and management options of lymphoplasmacytic lymphoma.
  • The patient responded well to emergent ES treatment with high-dose steroids and intravenous immunoglobulin.
  • Investigation revealed lymphoplasmacytic lymphoma (LPL) as well as amyloidosis in the hard palate, lymph nodes, and pericardium.
  • The patient developed neutropenic fever, atrial fibrillation and subsequently died.
  • ES contributed to his GI hemorrhage, severe anemia, and thus AMI at the time of presentation.
  • Instead of aggressive myelosuppressive chemotherapy agents, targeted therapies might be considered in these fragile patients.
  • [MeSH-major] Amyloidosis / complications. Anemia, Hemolytic, Autoimmune / complications. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Fatal Outcome. Humans. Immunoglobulins, Intravenous / therapeutic use. Male. Palate, Hard / pathology

  • Genetic Alliance. consumer health - Evans Syndrome.
  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291514.001).
  • [ISSN] 1744-2818
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Shimizu S, Tamagawa Y, Kojima H, Mori N, Nagata M, Noguchi M, Nagasawa T: Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes. Eur J Haematol; 2003 Feb;70(2):119-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous development of lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma--analyses of the clonal relatedness by sequencing CDR3 in immunoglobulin heavy chain genes.
  • A 75-yr-old male simultaneously having lymphoplasmacytic lymphoma (LPL) and diffuse large B-cell lymphoma (DLBCL) is presented.
  • Routine laboratory tests showed moderate pancytopenia, hypercalcemia (serum calcium, 15.9 mg/dL), IgM lambda-type monoclonal gammopathy (IgG, 405 mg/dL; IgA, 42 mg/dL; and IgM, 2023 mg/dL), and lambda-type Bence-Jones protein in the urine (0.8 g/d).
  • Bone marrow biopsy showed the clusters of surface lambda-positive small-sized mature-appearing lymphoplasmacytoid cells.
  • An open biopsy of the L3 tumor showed diffuse proliferation of CD20- and lambda-positive large cells.
  • Although the combination chemotherapy was at least partially effective, he died of bacteremia and organ failure after three courses of chemotherapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Clone Cells / pathology. Complementarity Determining Regions / genetics. Fatal Outcome. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Male. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12581194.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


13. Colvin JH, Lamerson CL, Cualing H, Mutasim DF: Cutaneous lymphoplasmacytoid lymphoma (immunocytoma) with Waldenström's macroglobulinemia mimicking rosacea. J Am Acad Dermatol; 2003 Dec;49(6):1159-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphoplasmacytoid lymphoma (immunocytoma) with Waldenström's macroglobulinemia mimicking rosacea.
  • A 50-year-old woman presented with a 2-year history of facial lesions that were resistant to rosacea therapy.
  • Evaluation of histology, immunohistochemistry, gene rearrangement study, bone-marrow biopsy specimen, and systemic workup revealed the findings of lymphoplasmacytoid lymphoma (immunocytoma) in both the skin lesions and bone marrow, and IgM kappa paraprotein.
  • Lesions cleared after chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Rosacea / pathology. Skin Neoplasms / pathology. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Bone Marrow Cells. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunoglobulin M / analysis. Immunoglobulin kappa-Chains / analysis. Immunohistochemistry. Leukemia, Lymphocytic, Chronic, B-Cell. Middle Aged. Paraproteins / analysis

  • MedlinePlus Health Information. consumer health - Rosacea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14639408.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Immunoglobulin kappa-Chains; 0 / Paraproteins
  •  go-up   go-down


14. Won YW, Kim SJ, Kim K, Ko YH, Kim WS: Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. Ann Hematol; 2010 Oct;89(10):1011-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea.
  • Lymphoplasmacytic lymphoma (LPL) constitutes less than 5% of all non-Hodgkin lymphomas, and little is known about clinical features and treatment outcomes for patients with LPL in East Asia.
  • LPL was more common among males (77.3%), with a median age of diagnosis of 63 years (range 26-86).
  • The most common presenting symptom was fatigue related to anemia (59.1%), and the bone marrow was commonly involved at diagnosis (90.9%).
  • Although some patients could be observed without treatment, the majority of patients required systemic treatment.
  • Chlorambucil alone and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like combination chemotherapy was frequently used as a first-line treatment, and a fludarabine-based regimen was commonly used as salvage therapy.
  • However, responses to those treatments were not satisfactory.
  • Even patients who could be monitored without therapy became refractory to salvage therapies once their disease progressed.
  • This study describes the clinical features and treatment outcome of LPL in Korea.
  • The treatment approach was too heterogeneous to draw firm conclusions, however, and treatment recommendations in the future should utilize a uniform treatment strategy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Waldenstrom Macroglobulinemia
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Disease Progression. Doxorubicin. Female. Humans. Korea. Male. Middle Aged. Prednisone. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449747.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M, Gribben JG, Marks DI: The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology; 2008 Apr;13(2):119-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.
  • Lymphoplasmacytic lymphoma (LL) is incurable by standard therapy (median survival: 60 months).
  • Nine patients received high dose chemotherapy [plus total body irradiation (TBI) in 1/9] and autologous peripheral blood stem cells (PBSC).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Waldenstrom Macroglobulinemia / therapy
  • [MeSH-minor] Adult. Female. Great Britain / epidemiology. Humans. Karnofsky Performance Status. Male. Middle Aged. Registries. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616880.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Escribano L, Pérez de Oteyza J, Núñez R, Orfao A: Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma. Leuk Res; 2002 Nov;26(11):1043-6
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma.
  • In the present paper a case of a 65-year-old man diagnosed as suffering from a lymphoplasmacytic lymphoma, resistant to conventional chemotherapy, associated to a bone marrow (BM) mastocytosis, who was successfully treated with cladribine is reported.
  • In this patient cladribine induced not only clinical remission of the lymphoplasmacytic lymphoma but it was also associated with immunophenotypical changes in the BM mast cells (MCs) compartment.
  • Such changes were consistent with a decrease in the number of phenotypically aberrant (CD2+/CD25++/CD35++/CD69++/CD117++) MCs and the reappearance in the BM of MCs displaying a normal phenotype (CD2-/CD25-/CD35-/CD69+/CD117+++).
  • Despite the potential utility of cladribine in the treatment of mastocytosis, our observations should be considered as preliminary and caution should be taken as regards the exact indications of the use of this purine analog in mastocytosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / drug effects. Cladribine / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Mast Cells / drug effects. Mastocytosis / drug therapy

  • Genetic Alliance. consumer health - Mast cell disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12363474.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


17. Zgouras D, Engels K, Lindhoff-Last E: Lymphoplasmacytic lymphoma with Waldenstrom's macroglobulinemia as a reason for peripheral arterial perfusion disorders. Vasa; 2009 May;38(2):193-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoplasmacytic lymphoma with Waldenstrom's macroglobulinemia as a reason for peripheral arterial perfusion disorders.
  • We report about a case of a 42-year-old female with peripheral arterial perfusion disturbances of the digital arteries caused by Waldenstrom s disease due to high plasma viscosity.
  • Plasma separation is the most effective acute treatment for symptomatic hyperviscosity syndrome.
  • Waldenstrom have to be treated by chemotherapy.
  • [MeSH-major] Blood Viscosity / physiology. Fingers / blood supply. Fingers / pathology. Ischemia / etiology. Peripheral Vascular Diseases / etiology. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Adult. Alprostadil / therapeutic use. Anticoagulants / therapeutic use. Biopsy. Blood Protein Electrophoresis. Bone Marrow / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunoglobulin Heavy Chains / blood. Immunoglobulin Light Chains / blood. Immunoglobulin lambda-Chains / blood. Necrosis. Tomography, X-Ray Computed. Ultrasonography, Doppler, Color. Vasodilator Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588311.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin lambda-Chains; 0 / Vasodilator Agents; F5TD010360 / Alprostadil
  •  go-up   go-down


18. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV: Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. J Clin Oncol; 2009 May 20;27(15_suppl):8513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
  • : 8513 Background: Waldenström's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma that is responsive to rituximab.
  • Clinicians who treat patients that achieve a minor response are left uncertain as to whether the response is adequate and patients should be monitored for progression or whether they should be considered therapy failures and crossover to an alternate chemotherapy regimen in an effort to achieve a deeper response.
  • All patients were treated with a single four-week course of rituximab 375 mg/m<sup>2</sup> and were monitored with no further therapy until progression.
  • There was no difference between objective and minor responders by age, time from diagnosis to treatment in the treated group, bone marrow lymphoplasmacytes, hemoglobin level, creatinine, IgM level, or M-spike.
  • The pre-treatment level of IgM did not predict overall survival, progression-free survival, time to progression, or response rate (All p>0.05).
  • CONCLUSIONS: These results reconfirm rituximab's efficacy as a single-agent for the treatment of Waldenström's macroglobulinemia, and patients who have a 25-50% reduction in their IgM protein derive significant clinical benefits that are durable and appear to not have an impact on overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ghobrial IM, McCormick DJ, Kaufmann SH, Ansell SM, Novak AJ, Stenson MJ, Krajnik KL, Witzig TE: Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):6530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy.
  • : 6530 Background: We employed antibody protein microarrays to measure changes in the patterns of protein expression between normal B-lymphocytes and those from patients with mantle cell lymphoma (MCL).
  • Another patient with lymphoplasmacytic lymphoma (LPL) was performed for comparison to confirm that the pattern of expression is unique to MCL.
  • RESULTS: Of the 6 MCL patients, 1 patient was heavily pretreated with chemotherapy and autologous stem cell transplantation and showed a distinct protein pattern from the other MCL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016943.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T: Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
  • : e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab.
  • We conducted a multicenter phase II study to investigate efficacy and toxicity of cladribine with rituximab (R-2-CdA) therapy for relapsed indolent B-NHL.
  • METHODS: Eligibility criteria were as follows: relapsed pts with indolent B-NHL from systemic chemotherapy, ages less than 75 years; PS 0-2 by ECOG's scale.
  • RESULTS: A total of 20 out of 45 planned patients were enrolled and received R-2-CdA therapy from Apr 2005 to Jul 2007.
  • Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma.
  • Median PFS was 20.1 months (5.6-32.9 months) at a median follow-up time of 27 months.
  • CONCLUSIONS: R-2CdA therapy was demonstrated to have high activity with durable PFS and acceptable toxicity in relapsed indolent B-NHL, even if patients were previously treated with rituximab.
  • Although a large-scaled further trial remains to be needed, R-2-CdA therapy could be a good option of salvage therapy in relapsed indolent B-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Thiel E, Jahnke K, Wagner T, Bechrakis NE, Coupland SE, Schmittel A, Fischer L, Foerster MH, Korfel A: Ifosfamide for intraocular lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):1520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide for intraocular lymphoma.
  • : 1520 Background: Intraocular lymphoma (IOL) occurs as a manifestation of a primary central nervous system lymphoma (PCNSL) or as ocular involvement of a systemic lymphoma.
  • The treatment of IOL has not yet been defined, since the data has been limited to small, usually retrospective treatment series or case reports.
  • CNS relapse is the rule after local treatment modalities.
  • Pt 2, a 46-year-old man, had a PCNSL resistant to 3 chemotherapy regimens and relapsed after RT in both eyes.
  • Pt 3, a 77-year-old man, had secondary IOL due to newly diagnosed immunocytoma.
  • Pts 1 and 2 received either 150 mg or 400 mg/day of trofosfamide PO on days 1-5 followed by a five-day drug-free interval.
  • Pt 4, who is still under treatment, had a partial remission after one cycle with VA normalization.
  • No significant therapy-related side effects were noted in all pts.
  • CONCLUSIONS: Ifosfamide seems to be active in IOL with a favorable side effect profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia; 2009 Jan;23(1):153-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
  • Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy.
  • This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM).
  • A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome.
  • With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P=0.0033) and in the WM subgroup (P=0.0241).
  • There was no major difference of treatment-associated toxicity between both treatment groups.
  • These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Humans. Middle Aged. Prednisone / therapeutic use. Remission Induction. Rituximab. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818699.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Hiddemann W, Dreyling M, Unterhalt M: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol; 2003 Feb;30(1 Suppl 2):16-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
  • Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma.
  • In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies.
  • Therefore, randomized phase III studies have been undertaken to determine whether rituximab plus chemotherapy can significantly improve outcomes compared with conventional chemotherapy in indolent non-Hodgkin's lymphoma.
  • A study by the German Low-Grade Study Group has evaluated rituximab in combination with FCM (fludarabine/cyclophosphamide/mitoxantrone) in a randomized setting versus FCM alone in patients with relapsed or refractory follicular, mantle cell, or lymphoplasmacytic lymphoma.
  • Superiority of rituximab plus FCM was seen in both follicular lymphoma (n = 53; ORR 92% v 75%; CR 40% v 21%) and, most strikingly, in mantle cell lymphoma (n = 38; ORR 65% v 33; CR 35% v 0%).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Clinical Trials as Topic. Cyclophosphamide / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / administration & dosage. Rituximab

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12652460.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Number-of-references] 27
  •  go-up   go-down


24. Clavio M, Quintino S, Venturino C, Ballerini F, Varaldo R, Gatto S, Galbusera V, Garrone A, Grasso R, Canepa L, Miglino M, Pierri I, Gobbi M: Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? J Exp Clin Cancer Res; 2001 Sep;20(3):351-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
  • Lymphoplasmacytic-lymphoplasmacytoid lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) or immunocytoma (IMC) consists of diffuse proliferation of small mature B lymphocytes, plasmacytoid lymphocytes, and plasma-cells.
  • The nosographic definition includes the lack of histological, immunophenotypic, cytogenetic, and molecular markers considered specific of other types of lymphoma.
  • The cells show surface Ig (usually IgM), B-cell-associated antigens and display the CD5-, CD23- and CD10- phenotype, which allows for differential diagnosis from B-CLL and mantle cell lymphoma. t(9;14)(p13;q32) chromosomal translocation has been found in 50% of all LPL cases.
  • The combination of chlorambucil and prednisone holds as the standard treatment and seems to guarantee good control of the disease in most patients.
  • Similar therapeutic results have been described with the combination of cyclophosphamide, vincristine, prednisone with (CHOP) or without doxorubicin (CVP), or with a combination of other alkylating agents and prednisone.
  • Nucleoside analogues, alone or in combination with alkylating agents and anthracyclines, provide good salvage therapy for IMC and being increasingly employed as first line therapy.
  • Therapy was well tolerated by all patients, and there was no decrease in cellular immune function, or significant infectious morbidity.
  • Furthermore, Weide et al. first reported that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab.
  • Most published trials exploring the efficacy of high dose treatment as salvage therapy for relapsed or refractory low grade non Hodgkin's lymphoma have included prevalently follicular or lymphocytic lymphomas.
  • In selected high risk patients radioimmunotherapy with autologous stem-cell rescue, and myeloablative therapy followed either by autologous stem cell transplantation (SCT) or allogeneic SCT might represent an alternative strategy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes / pathology. Diagnosis, Differential. Humans. Immunophenotyping. Immunotherapy. Lymphoproliferative Disorders / immunology. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11718214.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 46
  •  go-up   go-down


25. Neuhaus T, Pötzsch B, Ko Y, Köhler G, Brackmann HH, Vetter H: [Recurrent spontaneous hemorrhage in a patient with light chain immunocytoma]. Praxis (Bern 1994); 2002 Jan 23;91(4):112-8
MedlinePlus Health Information. consumer health - Bone Marrow Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent spontaneous hemorrhage in a patient with light chain immunocytoma].
  • [Transliterated title] Rezidivierende Spontanblutungen bei einer Patientin mit Leichtketten-Immunozytom.
  • The 48-year-old female patient was sent to our clinic for further evaluation of a spontaneous decrease of prothrombin- and prolongation of the bleeding-time.
  • The laboratory results revealed a pronounced decrease of prothrombin-time, a prolonged activated partial thromboplastin-time, a decrease of factor VII and X activity and a light chain paraprotein.
  • The histological examination of the bone marrow led to the diagnosis of an immunocytoma and a medullar amyloidosis.
  • For the aim of influencing the coagulopathy the patient was treated with chemotherapy.
  • However, she developed severe bleedings.
  • Under substitution of factor VIII-von Willebrand-factor-complex and chemotherapeutic treatment a stabilisation over several years was achieved till the patient died due to an amyloid-associated acute pancreatitis.
  • [MeSH-major] Amyloidosis / complications. Bone Marrow Diseases / complications. Hemorrhage / etiology. Immunoglobulin lambda-Chains. Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • [MeSH-minor] Blood Coagulation Tests. Diagnosis, Differential. Female. Humans. Middle Aged. Prothrombin Time. Recurrence

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11851036.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


26. Fijołek J, Wiatr E, Szołkowska M, Oniszh K: [Cytomegalic disease as a cause of disseminated lung lesions in an immunosuppressed patient]. Pneumonol Alergol Pol; 2000;68(9-10):454-62
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 54-year old patient treated since 10 years because of lymphoplasmacytoid lymphoma of low malignancy was admitted to Institute of Tuberculosis with suspicion of miliary tuberculosis.
  • The high temperature, pemphigus--like skin lesions and disseminated lesions in the chest X-ray appeared immediately after succeeding chemotherapy.
  • [MeSH-major] Cytomegalovirus Infections / diagnosis. Cytomegalovirus Infections / etiology. Immunosuppression / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lung Diseases / diagnosis. Lung Diseases / etiology
  • [MeSH-minor] Autopsy. Bronchoalveolar Lavage Fluid / cytology. Diagnosis, Differential. Fatal Outcome. Humans. Lung / radiography. Male. Middle Aged. Tuberculosis, Pulmonary / diagnosis

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11276977.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


27. Patriarca F, Silvestri F, Fanin R, Zaja F, Sperotto A, Baccarani M: Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol; 2001 Feb;112(2):370-2
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
  • Several epidemiological data suggest the involvement of hepatitis C virus (HCV) in the pathogenesis of some histotypes of B-cell non-Hodgkin's lymphomas, in particular immunocytoma.
  • We report a patient with HCV-associated immunocytoma, first treated with six courses of fludarabine.
  • A partial response was achieved and subsequent therapy with alpha-interferon resulted in the clearance of the virus and a long-lasting complete clinical and histological remission of the lymphoproliferative disease.
  • [MeSH-major] Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents / therapeutic use. Male. Recombinant Proteins. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11167831.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


28. Rourke M, Anderson KC, Ghobrial IM: Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma; 2010 Oct;51(10):1779-92
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
  • Many novel therapeutic agents are being tested in clinical trials for Waldenstrom macroglobulinemia (WM).
  • However, given the paucity of large clinical trials in WM, the establishment of a standard treatment regimen that can be used for comparison of response has become challenging.
  • Systematic searches of the PubMed and Medline databases, including The Cochrane Library, were performed for the search terms: clinical trials, Waldenstrom, macroglobulinemia, and lymphoplasmacytic lymphoma.
  • Based on this review, we recommend new response criteria and definitions of time to event analysis to be used in future clinical trials of WM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Chlorambucil / therapeutic use. Cladribine / therapeutic use. Drug Therapy, Combination. Humans. Rituximab. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Oct;51(10):1765-6 [20846101.001]
  • [CommentIn] Leuk Lymphoma. 2010 Oct;51(10):1767-70 [20919859.001]
  • (PMID = 20795787.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


29. Pels H, Vogt I, Klockgether T, Schlegel U: Primary non-Hodgkin's lymphoma of the spinal cord. Spine (Phila Pa 1976); 2000 Sep 1;25(17):2262-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the spinal cord.
  • OBJECTIVE: To report a rare case of primary lymphoma of the spinal cord and to discuss therapeutic options.
  • Prognosis is often poor, and therapy is not yet established.
  • METHODS: A primary lymphoplasmacytoid lymphoma of the thoracic cord in a 75-year-old woman was treated with focal radiotherapy (30 Gy) and three cycles of chemotherapy consisting of procarbazine, lomustine, and vincristine.
  • The patient was in complete remission at last follow-up (11 months after diagnosis).
  • CONCLUSIONS: Primary spinal cord lymphomas should be considered in the differential diagnosis of spinal cord tumors, especially in older patients.
  • Combination therapy with radiotherapy and chemotherapy may be superior to radiotherapy alone in these tumors.
  • Rapid initiation of treatment is essential to achieve recovery of neurologic function.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Thoracic Vertebrae. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973412.001).
  • [ISSN] 0362-2436
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


30. Louw VJ, Webb MJ: Prognosis and treatment of Waldenström's macroglobulinemia. Transfus Apher Sci; 2010 Apr;42(2):193-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and treatment of Waldenström's macroglobulinemia.
  • Waldenström's macroglobulinemia is classified by the World Health Organization (WHO) as one of the mature B cell lymphomas.
  • It is a rare clinical entity characterized by a serum monoclonal IgM with morphological evidence of lymphoplasmacytic lymphoma and a specific immunophenotype.
  • Due to the scarcity of the disease, the most optimal therapeutic strategy has not yet been identified.
  • There are, however, a number of active agents used in the treatment of this disease.
  • In this paper we will examine the prognostication of the disease, with emphasis on the International Prognostic Scoring System for Waldenström's macroglobulinemia (IPSSWM), and outline current therapeutic options.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20117052.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin M
  •  go-up   go-down


31. Johnson SA: Advances in the treatment of Waldenström's macroglobulinemia. Expert Rev Anticancer Ther; 2006 Mar;6(3):329-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the treatment of Waldenström's macroglobulinemia.
  • Waldenström's macroglobulinemia is a distinct disorder characterized by a monoclonal immunoglobulin M paraprotein and morphological evidence of lymphoplasmacytic lymphoma.
  • The aim of treatment for patients with Waldenström's macroglobulinemia should be to improve the quality and duration of life with minimal side effects in the most cost-effective manner.
  • It is not yet clear if achievement of a complete remission confers clinical benefit and it is possible that prolonging therapy to maximal response may increase toxicity without extra benefit.
  • There are no comparative data but alkylating agent-based treatments, combination therapy or purine analogs are all suitable choices for the initial therapy of patients requiring treatment.
  • In younger patients, in whom high-dose treatment is contemplated, there is a role for the use of rituximab; however, it should be administered with caution in patients with high levels of immunoglobulin M paraprotein or signs of hyperviscosity because of the risk of 'flare' in the paraprotein level and consequent adverse clinical events.
  • [MeSH-major] Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503850.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


32. Mori A, Tamaru J, Sumi H, Kondo H: Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol; 2002 Apr;68(4):243-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.
  • A case is reported of lymphoplasmacytoid lymphoma (LPL) associated with a monoclonal immunoglobulin (Ig) M and cold agglutinin disease (CAD) that was successfully treated with rituximab.
  • A 52-yr-old male was admitted with a direct antiglobulin test positive haemolytic anaemia and thrombocytopenia associated with monoclonal IgM.
  • Bone marrow examinations disclosed the marked infiltration of medium-sized lymphoma cells with plasmacytoid differentiation that indicated non-Hodgkin's lymphoma of B-cell origin (LPL).
  • Prednisolone and combination chemotherapy were temporarily effective for both anaemia and thrombocytopenia, although these strategies became refractory and bone marrow lymphoplasmacytosis persisted.
  • CAD ameliorated, and the serum level of IgM decreased in association with the disappearance of lymphoma cells and clonal rearrangement of the Ig heavy chains in the bone marrow after treatment with rituximab.
  • Rituximab played a significant role in the treatment of refractory CAD associated with LPL.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Cold Agglutinin Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12071942.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoglobulin M; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Rosales CM, Lin P, Mansoor A, Bueso-Ramos C, Medeiros LJ: Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with Hodgkin disease. A report of two cases. Am J Clin Pathol; 2001 Jul;116(1):34-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with Hodgkin disease. A report of two cases.
  • Although the clinical course of lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) is usually indolent, high-grade non-Hodgkin lymphoma may develop in a small subset of patients.
  • In case 1, the patient had LPL/WM involving bone marrow diagnosed 1 week before left supraclavicular lymph node biopsy revealed LPL/WM and classical HD.
  • In case 2, the patient had a 15-year history of LPL/WM before classical HD developed involving bone marrow, liver, and lymph node.
  • Both patients were treated with chemotherapy for HD.
  • In case 2, HD was progressive at last follow-up, despite therapy.
  • Patients with LPL/WM, similar to patients with other types of low-grade B-cell lymphoma, can develop HD that may respond to chemotherapy.
  • [MeSH-major] Hodgkin Disease / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Waldenstrom Macroglobulinemia / complications


34. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K, IDEC-C2B8 Study Group in Japan: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol; 2002 Jun;13(6):928-43
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
  • BACKGROUND: The aim of the study was to determine factors affecting the toxicity and efficacy of rituximab monotherapy in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma (MCL).
  • Central pathology review revealed that histologically, 81 patients had indolent B-cell lymphoma or MCL: 59 with follicular lymphoma, 17 with MCL, four with marginal zone lymphoma and one with lymphoplasmacytoid lymphoma.
  • Pre-treatment variables affecting toxicities were analyzed for all 90 patients, and those affecting response and progression-free survival (PFS) were analyzed for 77 eligible patients with confirmed indolent B-cell lymphoma or MCL.
  • The overall response rate (ORR) in patients receiving one prior chemotherapy regimen was higher than those receiving two or more regimens (P <0.05).
  • The median PFS was shorter in MCL patients, in those with extranodal disease, or in those receiving two or more prior chemotherapy regimens (P <0.01).

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12123339.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


35. Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD, Cancer and Leukemia Group B: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol; 2008 Feb;140(3):313-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.
  • Eleven patients progressed during therapy.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction / methods. Thromboembolism / chemically induced. Treatment Failure

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217897.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


36. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N: Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol; 2002 May 1;20(9):2327-33
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Waldenström's macroglobulinemia with rituximab.
  • PURPOSE: Waldenström's macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma in which CD20 is usually expressed on tumor cells.
  • There is evidence that patients with WM may benefit from treatment with the anti-CD20 monoclonal antibody rituximab.
  • RESULTS: Twelve patients (44%; 95% confidence interval, 25.5% to 64.7%) achieved a partial response after treatment with rituximab.
  • Median time to response was 3.3 months (range, 2.2 to 7.1 months).
  • Patients with a serum immunoglobulin M less than 40 g/L had a significantly higher response rate.
  • The median time to progression for all patients was 16 months, and with a median follow-up of 15.7 months, nine of 12 responding patients remain free of progression.
  • Treatment with rituximab was well tolerated, with approximately one fourth of patients experiencing some mild form of infusion-related toxicity, usually fever and chills.
  • Furthermore, studies that will combine rituximab with chemotherapy may be relevant.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Prospective Studies. Rituximab. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981004.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


37. Malkani RG, Tallman M, Gottardi-Littell N, Karpus W, Marszalek L, Variakojis D, Kaden B, Walker M, Levy RM, Raizer JJ: Bing-Neel syndrome: an illustrative case and a comprehensive review of the published literature. J Neurooncol; 2010 Feb;96(3):301-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenstrom's macroglobulinemia (WM) is a chronic lymphoproliferative disorder within the spectrum of lymphoplasmacytic lymphoma characterized by proliferation of plasma cells, small lymphocytes, and plasmacytoid lymphocytes.
  • We performed a Medline search using the terms "Waldenstrom's macroglobulinemia and central nervous system" and "Bing-Neel" collecting data on presentation, evaluation, treatment, and outcome and summarizing these findings in the largest pooled series to date.
  • Cerebrospinal fluid analysis may show lymphocytic pleocytosis, elevated protein, and IgM kappa or lambda light chain restriction; cytology results are variable.
  • Biopsy confirms the diagnosis.
  • Treatment data are limited, but responses are seen with radiation and/or chemotherapy.
  • Treatment should be initiated as responses do occur that may improve quality of life and extend it when limited or no active systemic disease is present.
  • [MeSH-major] Headache / complications. Neurodegenerative Diseases / complications. Waldenstrom Macroglobulinemia / complications

  • MedlinePlus Health Information. consumer health - Degenerative Nerve Diseases.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2011 Sep;104(2):615 [21221713.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1215-9 [10098762.001]
  • [Cites] Ann Intern Med. 1984 Sep;101(3):345-7 [6431863.001]
  • [Cites] Neurology. 2008 Apr 15;70(16):1364 [18413593.001]
  • [Cites] J Lab Clin Med. 1965 Aug;66:280-93 [14322074.001]
  • [Cites] Presse Med. 1990 Dec 15;19(43):1992 [2149607.001]
  • [Cites] Acta Neurol Scand. 1969;45(1):1-17 [5803588.001]
  • [Cites] Acta Haematol. 1993;90(4):206-8 [8140863.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):838-41 [10929038.001]
  • [Cites] Neurochirurgie. 1997;43(4):245-9 [9686227.001]
  • [Cites] Neurology. 1961 Mar;11:239-45 [13725698.001]
  • [Cites] Neurology. 2005 Feb 8;64(3):576-7 [15699407.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1243-4 [12385333.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):80-2 [16827886.001]
  • [Cites] Arch Neurol. 1960 Nov;3:564-73 [13763183.001]
  • [Cites] Ann Anat Pathol (Paris). 1966 Jul-Sep;11(3):309-13 [4961291.001]
  • [Cites] J Clin Neurosci. 2007 Jun;14(6):601-3 [17376690.001]
  • [Cites] J Korean Med Sci. 2007 Dec;22(6):1079-81 [18162727.001]
  • [Cites] Rev Neurol (Paris). 1991;147(1):56-60 [1901664.001]
  • [Cites] Rev Neurol. 2004 Apr 1-15;38(7):640-2 [15098185.001]
  • [Cites] Neurology. 1983 Nov;33(11):1411-5 [6415510.001]
  • [Cites] Ann Med Interne (Paris). 1989;140(1):25-9 [2500048.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):203-6 [10613467.001]
  • [Cites] J Neuropathol Exp Neurol. 1984 Jul;43(4):408-25 [6429288.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3344-9 [17577016.001]
  • [Cites] Rev Med Interne. 1992 Jan-Feb;13(1):58-60 [1410876.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2694-8 [7989946.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):132-8 [15598950.001]
  • [Cites] Policlinico Prat. 1969 Mar 31;76(13):401-22 [4097396.001]
  • [Cites] Eur Neurol. 1972;7(3):155-68 [4112851.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):127-31 [11835349.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2476 [7666113.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Aug;35(8):575-9 [7566387.001]
  • (PMID = 19618118.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 36
  •  go-up   go-down


38. Johnson SA, Oscier DG, Leblond V: Waldenström's macroglobulinaemia. Blood Rev; 2002 Sep;16(3):175-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenström's macroglobulinaemia (WM) is most usefully defined as a distinct chronic lymphoproliferative disorder with characteristic marrow morphology and phenotype; although nodal morphology if available will reveal a lymphoplasmacytoid lymphoma, the presence of a significant IgM paraprotein defines the clinical features of the disease.
  • The clonal cell is a B-cell expressing IgM, CD19, and CD20 but not IgD, CD5, CD10 or CD23 and has somatic hypermutation of immunoglobulin heavy chain variable regions consistent with a post-germinal centre origin.
  • Treatment of WM has been dependent on alkylating agents with or without coriticosteroids for many years, supplemented by the use of therapeutic plasmapheresis in the initial stages for patients at risk from the clinical consequences of hyperviscosity.
  • This approach to treatment results in response rates of approximately 60% with a median survival of about 60 months.
  • There is increasing evidence to show that the purine analogues fludarabine and cladribine which are active in the treatment of patients who are resistant to alkylating agents such as chlorambucil may be able to achieve higher response rates when used as initial therapy.
  • A prospective trial is being undertaken to compare fludarabine and chlorambucil as initial treatment; because of the effect of subsequent active treatment on patients who do not respond to the first treatment choice, the long-term outcome may be similar for both groups.
  • Recent advances in therapy include the use of therapeutic monoclonal antibodies such as rituximab and the use of autologous or allogeneic transplant procedures for selected patients.
  • [MeSH-major] Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Research. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12163003.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 52
  •  go-up   go-down


39. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol; 2000 Jan;18(2):317-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
  • PURPOSE: Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy.
  • Restaging studies were performed 1 and 2 months after treatment.
  • There were 31 episodes of infection after treatment; most cases were mild.
  • The duration of response in MCL was similar to that previously reported in follicular lymphoma.
  • Its use in combination with cytotoxic chemotherapy to increase the CR rate is warranted in MCL and IMC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Mantle-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol 2000 May;18(9):2006
  • (PMID = 10637245.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


40. Audouin J, Le Tourneau A, Molina T, Camilleri-Broët S, Adida C, Comperat E, Benattar L, Delmer A, Devidas A, Rio B, Diebold J: Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol; 2003 Aug;122(3):404-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes.
  • We studied 86 bone marrow biopsies (BMB) from 58 patients presenting with primary splenic marginal zone lymphoma (PSMZL).
  • In 42 patients, a splenectomy was performed which enabled a histopathological diagnosis.
  • In 16 recently observed patients, 17 BMB led to PSMZL diagnosis, and these patients were treated without splenectomy.
  • Seven different patterns of infiltrates were recognized: intravascular, interstitial, nodular, massive, plasmacytic mimicking myeloma and transformation into large B-cell lymphoma (DLBCL).
  • The association of an intravascular infiltrate and nodules with a germinal centre and/or a marginal zone favoured a diagnosis of MZL.
  • Immunohistochemistry demonstrated the expression of B cell-associated antigens and, in 40% of the patients, a monotypic lymphoplasmacytic cell component.
  • In the past, such cases have been diagnosed as lymphoplasmacytic lymphoma.
  • Successive biopsies showed progression and, after chemotherapy, a slight decrease in infiltrates.
  • The patterns described are not specific for PSMZL and occur also in primary nodal MZL and, more rarely, in MALT-type lymphoma.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow Cells / pathology. Leukemic Infiltration. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Plasma Cells / pathology. Splenectomy. Waldenstrom Macroglobulinemia / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2004 Jan;124(2):252-3 [14687039.001]
  • (PMID = 12877667.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C, East German Study Group Hematology and Oncology (OSHO): Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol; 2006 Feb;132(2):105-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
  • PURPOSE: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + prednisone (COP) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma.
  • METHODS: A total of 164 patients with follicular lymphoma (grade 1/2), mantle cell lymphoma or lymphoplasmacytic lymphoma (immunocytoma) was randomised to treatment with vincristine 2 mg (day 1) and prednisone 100 mg/m2 (days 1-5) + bendamustine 60 mg/m2 (days 1-5) or + cyclophosphamide 400 mg/m2 (days 1-5) for a total of eight 21-day cycles.
  • The BOP-associated 5-year survival advantage almost reached significance in the subgroup of patients who responded to therapy (74% vs. 56%; P = 0.05), and did reach significance in responders who did not receive interferon maintenance therapy (70% vs. 47%; P = 0.03).
  • Toxicity was acceptable in both treatment groups, although alopecia and leucopenia were more severe with COP.
  • CONCLUSIONS: Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Nitrogen Mustard Compounds / administration & dosage. Prednisone / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1670-2 [3655864.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] Ann Intern Med. 1972 Feb;76(2):227-34 [5066691.001]
  • [Cites] Biochem Pharmacol. 2003 Sep 1;66(5):711-24 [12948851.001]
  • [Cites] Internist (Berl). 1997 Nov;38(11):1131-42 [9453969.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]
  • (PMID = 16088404.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 981Y8SX18M / Bendamustine Hydrochloride; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


42. Baehring JM, Hochberg EP, Raje N, Ulrickson M, Hochberg FH: Neurological manifestations of Waldenström macroglobulinemia. Nat Clin Pract Neurol; 2008 Oct;4(10):547-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological manifestations of Waldenström macroglobulinemia.
  • Waldenström macroglobulinemia, a condition that most commonly occurs in lymphoplasmacytic lymphoma, typically manifests with diffuse lymphadenopathies, cytopenias, and a markedly elevated erythrocyte sedimentation rate.
  • Diagnosis of Waldenström macroglobulinemia requires identification of monoclonal IgM protein in the serum, bone marrow biopsy, and appropriate neurological testing (e.g. imaging studies of affected areas of the central neuraxis, electrophysiological studies).
  • Treatment options, which should address both the paraprotein burden and the lymphoplasmacytic clone, include plasmapheresis and chemotherapy with alkylating agents, nucleoside analogs, and rituximab.
  • As the disease is incurable and its course indolent, these treatments are only provided to symptomatic patients.
  • [MeSH-major] Nervous System Diseases / etiology. Nervous System Diseases / physiopathology. Waldenstrom Macroglobulinemia / complications

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813229.001).
  • [ISSN] 1745-8358
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 92
  •  go-up   go-down


43. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR: Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma; 2004 Oct;45(10):2047-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
  • Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface.
  • Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Probability. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370249.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


44. Kraj M, Pogłód R, Kopeć-Szlezak J, Sokołowska U, Woźniak J, Kruk B: C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma; 2004 Nov;45(11):2281-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surface expression of CD117 antigen (c-kit) on plasma cells from 158 multiple myeloma (MM), 12 plasma cell leukemia (PCL), 7 MGUS, 7 IgM lymphoplasmacytic lymphoma patients and 10 healthy subjects has been analyzed by flow cytometry using triple staining with the monoclonal antibodies CD138, CD117 and CD38.
  • In responsive to chemotherapy c-kit positive MM patients the percentage of CD117+ plasma cells in the bone marrow decreased significantly while in c-kit negative MM patients the percentage of CD117+ cells in bone marrow did not change and remained in the normal limits.
  • When comparing the clinical and biological disease characteristics (monoclonal protein isotype, albumin, beta2-microglobulin, lactate dehydrogenase, stage of disease, response to chemotherapy, survival time) of c-kit positive and c-kit negative cases, no significant differences were found.
  • Normal plasma cells and those in IgM lymphoplasmacytic lymphoma did not show reactivity for the CD117 antigen.
  • We conclude that it may be rationale to consider usefulness of therapy with tyrosine kinase inhibitors in the management of c-kit positive plasma cell proliferations.
  • In one third of MM and PCL patients c-kit antigen could be considered as a "tumor associated marker" and together with CD38 and CD138 it may be of value for the identification of the malignant clone in minimal residual disease as it was first suggested by Spanish authors.
  • [MeSH-minor] ADP-ribosyl Cyclase / biosynthesis. Aged. Antigens / metabolism. Antigens, CD / biosynthesis. Antigens, CD38. Binding Sites. Biopsy. Disease-Free Survival. Female. Flow Cytometry. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Plasma Cell / metabolism. Male. Membrane Glycoproteins / biosynthesis. Microscopy, Fluorescence. Middle Aged. Multiple Myeloma / metabolism. Proteoglycans / biosynthesis. Remission Induction. Syndecan-1. Syndecans. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512818.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, CD; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


45. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B: Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol; 2001 Jun;113(3):772-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
  • A multicentre phase II trial was conducted to evaluate the efficacy and toxicity of gemcitabine in patients with refractory or relapsed indolent non-Hodgkin's lymphoma.
  • Thirty-six patients were enrolled onto the study, including 11 cases of mantle cell lymphoma (MCL), 10 cases of chronic lymphocytic leukaemia (CLL)/lymphocytic lymphoma, nine cases of follicular lymphoma, four cases of lymphoplasmacytic lymphoma and two cases of T-cell lymphoma.
  • Complete responses were observed in two patients with MCL, and partial responses were observed in seven patients, including three patients with CLL/lymphocytic lymphoma, two patients with T-cell lymphoma, one patient with MCL and one patient with follicular lymphoma.
  • Severe non-haematological toxicity included one case of fatal veno-occlusive disease, one case of thrombotic microangiopathy leading to terminal renal failure, one case of capillary leak syndrome, one case of myocardial infarction and drug-induced fever in two patients.
  • These data suggest that gemcitabine displays activity in patients with MCL and CLL/lymphocytic lymphoma.
  • [MeSH-major] Antimetabolites / therapeutic use. Deoxycytidine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Capillary Leak Syndrome / chemically induced. Disease-Free Survival. Drug Administration Schedule. Female. Fever / chemically induced. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukopenia / chemically induced. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Male. Middle Aged. Myocardial Infarction / chemically induced. Pulmonary Veno-Occlusive Disease / chemically induced. Recurrence. Renal Insufficiency / chemically induced. Survival Rate. Thrombocytopenia / chemically induced. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11380469.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


46. Farmer JP, Lamba M, Merkur AB, Lamba WR, Hodge WG, Jordan DR, Sengar DP, Burns BF: Characterization of lymphoproliferative lesions of the conjunctiva: immunohistochemical and molecular genetic studies. Can J Ophthalmol; 2006 Dec;41(6):753-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathologic, immunohistochemical, and molecular genetic features were characterized, as well as the frequency of tumour type, prognostic implications, clinical features, and treatments offered.
  • RESULTS: The diagnosis was lymphoma in 12 cases, atypical lymphoid hyperplasia (ALH) in 1 case, and reactive lymphoid hyperplasia (RLH) in 3 cases.
  • The primary lymphomas consisted of 4 mucosa-associated lymphoid tissue lymphomas (MALTL), 1 follicular lymphoma (FL), 2 diffuse large B-cell lymphomas (DLBCLs), 1 lymphoplasmacytic lymphoma, and 1 T-cell lymphoma.
  • Primary lymphomas were treated with radiation (n = 7), surgery (n = 1), and topical chemotherapy (n = 1).
  • Complete remission was seen in 2 patients after radiation plus chemotherapy, while the patient treated with chemotherapy alone was lost to follow-up.
  • The 1 case of ALH presented bilaterally and achieved complete remission after topical chemotherapy treatments.
  • BCL2-IgH [t(14;18)] rearrangement was seen in 8 of 12 cases (1 FL, 3 DLBCLs, 4 MALTLs) by real-time quantitative PCR.
  • INTERPRETATION: Conjunctival lymphomas are predominantly B-cell type with a high prevalence of MALTL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224959.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


47. Nickenig C, Dreyling M, Hoster E, Ludwig WD, Dörken B, Freund M, Huber C, Ganser A, Trümper L, Forstpointner R, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group: Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol; 2007 Jan;18(1):136-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
  • Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission.
  • The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens.
  • Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma.
  • In contrast, after MCP therapy stem cell collection was successful in only 15 of 34 patients (44%, 95% CI 27% to 62%; P=0.0003).
  • In conclusion, initial therapy with MCP significantly impairs the ability to collect stem cells and should be avoided for first line therapy of younger patients potentially qualifying for high dose consolidation and ASCT in first remission.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071931.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone
  •  go-up   go-down


48. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP, Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol; 2006 May 01;24(13):2105-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  • Plasma tumor necrosis factor alpha (TNF-alpha) and interleukin-6 were measured before each treatment, and bortezomib activity was examined in patient samples grown in primary culture.
  • RESULTS: Fifty-one patients received a total of 193 cycles of treatment.
  • Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia/lymphoma.
  • Patients were heavily pretreated with a median of four previous therapies.
  • Seven patients with MCL responded to treatment (one complete response, six partial responses [PRs]; overall response rate, 29%).
  • Two patients with FL achieved a late PR 3 months after discontinuing therapy.
  • Two patients with Waldenström's macroglobulinemia and one patient with HD achieved a PR.
  • A median reduction in plasma TNF-alpha of 98% was observed in six patients with MCL who responded to bortezomib compared with a reduction of 38% in six nonresponders (P = .07).
  • Response was associated with a reduction in plasma TNF-alpha and in vitro sensitivity in a small number of patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. Lymphoma / drug therapy. Pyrazines / therapeutic use. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Bortezomib. Cell Line, Tumor. Cell Survival / drug effects. Cytokines / blood. Doxorubicin / pharmacology. Female. Humans. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Cytokines; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin
  •  go-up   go-down


49. Bischof M, Zierhut D, Neuhof D, Karagiozidis M, Treiber M, Roeder F, Debus J, Krempien R: Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy. Ophthalmologica; 2007;221(5):348-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy.
  • AIMS: Primary non-Hodgkin's lymphoma (NHL) of the orbit is uncommon, representing approximately 8% of extranodal NHLs.
  • MATERIALS AND METHODS: The median age at first diagnosis was 63.5 years (range 24-82 years).
  • Extranodal mucosa-associated lymphoid tissue lymphoma (n = 15) was the most common histological subtype of NHL, followed by follicular (n = 6) and lymphoplasmacytic lymphoma (n = 1).
  • The median radiation dose was 40 Gy (range 30-46 Gy).
  • None of the patients received chemotherapy before irradiation.
  • The 5-year overall survival rate was 89%; there were no lymphoma-related deaths.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Orbital Neoplasms / pathology. Orbital Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cataract / etiology. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiation Dosage. Radiation Injuries / complications. Sjogren's Syndrome / etiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17728558.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


50. Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R, Pieramici T, Leoni P, Rubini C, Fabris G, Lo Muzio L: Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol; 2006 Apr-Jun;19(2):421-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.
  • This study correlates bone marrow changes after Rituximab (RTX) treatment with the clinical characteristics and outcome of 26 patients with small B-cell lymphomas.
  • The percentage, phenotypic profile and clonality pattern of bone marrow lymphoid infiltrate were analysed before and after RTX treatment.
  • A favourable histology--follicular lymphoma (FL), hairy cell leukaemia (HCL) and marginal zone lymphoma (MZL)--was associated with a higher frequency of clinical CR and histological remission (HR), in comparison with mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL) and lymphoplasmacytic lymphoma (LPL).
  • In conclusion, bone marrow morphological and immunohistochemical analysis with a restricted panel of antibodies is useful to avoid 42% false positive and 85% false negative interpretations.
  • Persistence of monoclonality after RTX might have a role in evaluating the molecular pattern of CD20-negative clones that can emerge after RTX as a tumoral escape to therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow / metabolism. Bone Marrow / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cloning, Molecular. Female. Follow-Up Studies. Humans. Lymphocytes / immunology. Male. Middle Aged. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831308.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


51. Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma; 2003 Jun;44(6):967-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
  • The role of high dose therapy, including autologous stem cell transplantation (ASCT) in indolent non-Hodgkin's lymphomas remains controversial.
  • We evaluated a dose intense regimen of CHOP induction followed by high dose cyclophosphamide consolidation (CHOP-HC) versus CHOP alone in a prospective comparison to assess intensified therapy without ASCT.
  • Twenty-five patients with previously untreated advanced stage indolent NHL were enrolled: follicular lymphoma, grade 1 (11 patients) and grade 2 (8 patients); small lymphocytic lymphoma (5 patients); and lymphoplasmacytic lymphoma (1 patient).
  • There were no treatment-related deaths.
  • With no obvious improvement in CR and with greater hematologic toxicity than CHOP, CHOP-HC is not recommended for treatment of indolent non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Rate. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP protocol, modified
  •  go-up   go-down


52. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol; 2008 Sep;142(5):775-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
  • Waldenstrom macroglobulinaemia (WM) is an incurable lymphoplasmacytic lymphoma with secretion of serum monoclonal immunoglobulin M (IgM).
  • Simvastatin also decreased IgM secretion by BCWM.1 cells at an early time-point that had not affected cell survival.
  • [MeSH-major] Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Simvastatin / pharmacology. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Immunoglobulin M / metabolism. In Vitro Techniques. Proto-Oncogene Proteins c-akt / metabolism


53. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD: Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma; 2005 Sep;6(2):131-5
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
  • PATIENTS AND METHODS: We conducted a phase II trial with the combination regimen of PC-R (pentostatin/cyclophosphamide with or without rituximab) in 14 patients with Waldenstrom's macroglobulinemia (WM) and 3 patients with lymphoplasmacytic lymphoma (LL) without monoclonal serum immunoglobulin M (IgM), followed by a maintenance regimen with rituximab (375 mg/m2 every 3 months) for patients exhibiting a complete response (CR) or a partial response (PR) after 4-6 cycles.
  • The first 9 patients received PC therapy (pentostatin 4 mg/m2 plus cyclophosphamide 600 mg/m2), and 8 patients received the same combination with rituximab 375 mg/m2 on day 1.
  • In 3 patients with a PR after completion of chemotherapy, remission has improved further, with normalization of the IgM level in 1 patient and another patient exhibiting a CR.
  • Maintenance therapy with rituximab for WM as a single infusion every 3 months can be administered safely and can improve remission status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Waldenstrom Macroglobulinemia / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231851.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoglobulin M; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


54. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA: Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J; 2000;1(6):367-73
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
  • INTRODUCTION: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies.
  • PATIENTS AND METHODS: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 microg/kg/day).
  • The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients).
  • The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years).
  • The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination.
  • At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in > or =2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients.
  • The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04).
  • CONCLUSION: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients.
  • These factors should be taken into account when patients are being considered for high-dose treatment.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920216.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


55. Silvestri F, Sperotto A, Fanin R: Hepatitis c and lymphoma. Curr Oncol Rep; 2000 Mar;2(2):172-5
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis c and lymphoma.
  • Epidemiologic data presented in this review suggest the involvement of hepatitis C virus (HCV) in the patho- genesis of some histotypes of B-cell non-Hodgkin's lymphoma, in particular immunocytoma and lymphomas growing primarily in the liver and major salivary glands.
  • Recent findings include demonstration that patients with hematologic malignancies can be treated safely with standard and high-dose chemotherapy even in the presence of HCV infection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hepatitis C / drug therapy. Hepatitis C / epidemiology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / epidemiology
  • [MeSH-minor] Animals. Comorbidity. Female. Humans. Male. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Epidemiol. 1992 Mar;8(2):309-11 [1379536.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Jun;11(6):669-72 [10418940.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):237-9 [9935205.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):475-80 [9401053.001]
  • [Cites] Br J Haematol. 1999 May;105(2):568-9 [10233441.001]
  • [Cites] Lancet. 1996 Mar 2;347(9001):624-5 [8596360.001]
  • [Cites] Blood. 1996 Jul 15;88(2):752-4 [8695825.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Blood. 1998 Jan 1;91(1):360 [9414306.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):841 [10354158.001]
  • [Cites] Leuk Res. 1996 May;20(5):445 [8683985.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):314-7 [9234578.001]
  • [Cites] Eur J Clin Invest. 1994 Nov;24(11):781-4 [7534236.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1209-13 [8684003.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1144-5 [7849303.001]
  • [Cites] Haematologica. 1999 Nov;84(11):1052-3 [10553172.001]
  • [Cites] Am J Med. 1999 May;106(5):556-60 [10335728.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1125-6 [8704227.001]
  • [Cites] Ann Oncol. 1998 May;9(5):499-504 [9653490.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5380-1 [8652854.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2433-42 [9516143.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Leukemia. 1996 Feb;10(2):351-5 [8637247.001]
  • [Cites] J Hepatol. 1998 Jan;28(1):34-9 [9537861.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1490-5 [1383822.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):255-8 [10077173.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):2032-5 [9667688.001]
  • [Cites] J Hepatol. 1994 Dec;21(6):1146-7 [7699244.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Lancet. 1996 May 11;347(9011):1339 [8622540.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2604-13 [8640712.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3047-53 [7949176.001]
  • [Cites] Clin Lab Haematol. 1998 Apr;20(2):107-10 [9681221.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23 (9):1124-30 [10478674.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):548-52 [7646992.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1224-30 [9740089.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):373-5 [8759899.001]
  • [Cites] Haematologica. 1995 Sep-Oct;80(5):486-7 [8566896.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):427-8 [9029041.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1778-9 [10084815.001]
  • [Cites] Haematologica. 1999 Jan;84(1):94-6 [10091402.001]
  • [Cites] Leuk Lymphoma. 1995 Dec;20(1-2):119-24 [8750632.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):544-50 [8790157.001]
  • [Cites] Leukemia. 1997 Dec;11(12):2157-61 [9447835.001]
  • (PMID = 11122840.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


56. Melegh Z, Sutak J, Whiteway A, Rooney N, Pawade J: Lymphomatoid granulomatosis of the uterine cervix. Pathol Res Pract; 2009;205(5):371-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomatoid granulomatosis is an Epstein-Barr virus-driven lymphoproliferative disorder, usually with a prominent pulmonary involvement and occasional extrapulmonary manifestations.
  • Here, we present a case of lymphomatoid granulomatosis confined to the uterine cervix at the initial diagnosis.
  • The disease was preceded by an immunosuppressive condition, namely low-grade lymphoplasmacytic lymphoma treated with chemotherapy.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Epstein-Barr Virus Infections / complications. Female. Humans. Immunohistochemistry. In Situ Hybridization. Palatine Tonsil / metabolism. Palatine Tonsil / pathology. RNA, Viral / analysis. Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147299.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral
  •  go-up   go-down


57. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C: Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J; 2004 Mar;167(2):158-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
  • The aim of this study was to determine the response of different morphological subtypes of canine lymphoma to a standardized therapeutic protocol.
  • Diagnosis of lymphoma was based on cytohistological analysis and immunophenotyping with antibodies against CD3 and CD79a of an enlarged lymph node or an extranodal mass.
  • Fifty-seven cases were classified according to the updated Kiel classification adapted to the canine species, into 24 B-cell lymphomas (20 centroblastic polymorphic and four Burkitt-type subtypes), and 33 T-cell lymphomas (10 pleomorphic mixed, 10 lymphoblastic, eight unclassifiable high grade plasmacytoid, and five small clear-cell subtypes).
  • All dogs were clinically staged at diagnosis.
  • First remission duration and overall survival time were evaluated.
  • Although the T-cell phenotype was associated, on the whole, with a poor prognosis, as previously reported in veterinary and human medicine, the study showed significant prognostic differences between the B- and the T-cell subtypes of canine lymphoma and suggests that clinico-morphological characterization of the disease is justified in dogs, as in humans.
  • [MeSH-major] Dog Diseases / classification. Dog Diseases / epidemiology. Lymphoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dogs. Female. France / epidemiology. Immunophenotyping / veterinary. Male. Prognosis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet J. 2004 Mar;167(2):125-6 [14975385.001]
  • (PMID = 14975390.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos N, Economopoulos T, Greek Myeloma Study Group: Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol; 2003 Aug;14(8):1299-305
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
  • BACKGROUND: Waldenstrom's macroglobulinemia (WM) is an unusual lymphoplasmacytoid lymphoma characterized by the presence of a serum monoclonal immunoglobulin M.
  • Although several studies have evaluated possible prognostic factors of this disease, few have focused on the survival and prognosis of symptomatic patients after the initiation of treatment.
  • PATIENTS AND METHODS: Our study included 122 previously untreated patients with a median age of 67 years who required systemic treatment.
  • Multiple variables were analyzed for their prognostic value on survival after initiation of treatment using univariate and Cox regression multivariate analysis.
  • Pretreatment factors associated with shorter survival were age >/=65 years, splenomegaly, B-symptoms (weight loss, fever or night sweats), hemoglobin <10 g/dl, platelets <100 x 10(6)/dl, albumin <3.5 g/dl and bone marrow lymphoplasmacytic infiltrate >/=50%.
  • The median survival times in the high-, intermediate- and low-risk groups were 46 months, 107 months and 172 months, respectively (P <0.0001).
  • DISCUSSION: Our findings suggest that advanced age and anemia appear to be the two dominant prognostic factors for survival after initiation of treatment in patients with WM.
  • These two readily available parameters can stratify the patients into three distinct subgroups and may help the selection of appropriate treatment.

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881396.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


59. Padate BP, Keidan J: Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol; 2006 Feb;28(1):69-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab.
  • A 75-year-old man, with a long history of recurrent lymphoplasmacytoid lymphoma, presented with diffuse large-cell lymphoma affecting adrenal glands and causing severe hypoadrenalism.
  • The lymphoma responded to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy.
  • Seven months postcompletion of chemotherapy, he developed signs of gastroenteritis and septicaemia.
  • He deteriorated 24 h postadmission with a significant fall in Glasgow Coma Scale Score.
  • We speculate that profound immunosuppression induced by rituximab, together with previous chemotherapy, predisposed this patient to fatal enteroviral meningoencephalitis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Enterovirus Infections / etiology. Immunosuppression / adverse effects. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Meningoencephalitis / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Fatal Outcome. Humans. Immunoglobulins, Intravenous / administration & dosage. Prednisone / administration & dosage. Prednisone / adverse effects. RNA, Viral / cerebrospinal fluid. Rituximab. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430465.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulins, Intravenous; 0 / RNA, Viral; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


60. Zinzani PL, Pulsoni A, Gentilini P, Visani G, Perrotti A, Molinari AL, Guardigni L, Tani M, Villivà N, Stefoni V, Alinari L, Martelli M, Bonifazi F, Pileri S, Tura S, Baccarani M: Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2004 Sep;45(9):1815-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
  • In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously untreated low-grade non-Hodgkin's lymphomas (LG-NHL).
  • We report on the therapeutic efficacy and toxicity of a combination of FLU, idarubicin and cyclophosphamide (FLUIC regimen) in untreated non-follicular LG-NHL.
  • We administered a three-drug combination of FLU (25 mg/m2 i.v. on days 1 to 3), idarubicin (14 mg/m2 i.v. on day 1) and cyclophosphamide (200 mg/m2 i.v. on days 1 to 3) to treat 41 young, previously untreated patients with non-follicular LG-NHL.
  • Chemotherapy was repeated every 4 weeks for a total of 6 cycles.
  • Among 41 patients, 24 (59%) were diagnosed with small lymphocytic, 10 (24%) with immnocytoma, and 7 (17%) with marginal zone subtypes.
  • Nineteen (46%) patients achieved complete response (CR) and 21 (51%) partial response, while the remaining 1 (3%) showed no benefit from the treatment.
  • With respect to histology, we observed CR rates of 38% for the small lymphocytic subtype, 40% for the immunocytoma subtype, and 86% for the marginal zone subtype.
  • [MeSH-major] Aging / physiology. Cyclophosphamide / therapeutic use. Idarubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223641.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


61. Kath R, Blumenstengel K, Fricke HJ, Peters HD, Höffken K: [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]]. Dtsch Med Wochenschr; 2001 Feb 23;126(8):198-202
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
  • [Transliterated title] Bendamustin, Vincristin, Prednisolon (BOP) in der Therapie von fortgeschrittenen niedrig malignen Non-Hodgkin-Lymphomen.
  • BACKGROUND AND OBJECTIVE: Low grade non-Hodgkin lymphomas (l-NHL) are rarely showing complete or sustained remissions to conventional chemotherapy.
  • Thus, many therapeutic strategies try to improve the remission rates and outcome in relapsed and refractory l-NHL.
  • Bendamustine (B) is a non-cross resistant alkylating agent shown to be highly effective in lymphoproliferative and other malignant diseases.
  • PATIENTS AND METHODS: 22 patients (median age 61.5 years, range 39-77 years) with relapsed or refractory low grade NHL: immunocytoma (IC) n = 11, centroblastic-centrocytic (CB-CC) n = 6, centrocytic (CC) n = 2, others n = 3, were treated with BOP as follows: patients up to 75 years: 60 mg/m2 B for 5 days; patients over 75 years: 50 mg/m2 B for 5 days.
  • Prior to BOP patients were pretreated with 1-4 chemotherapy protocols.
  • In most patients BOP was followed by a maintenance therapy (IFN-alpha n = 11, chlorambucil n = 4, etoposide n = 2).
  • CONCLUSION: Salvage therapy of refractory and relapsed l-NHL with BOP results in a high objective remission rate.
  • Together with a maintenance therapy most patients achieved a long-term disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11256023.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; COB protocol
  •  go-up   go-down


62. Mayerhofer M, Haushofer A, Kyrle PA, Chott A, Müllner C, Quehenberger P, Worel N, Traby L, Eichinger S: Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest; 2009 Sep;39(9):833-6
Genetic Alliance. consumer health - Acquired Von Willebrand syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired von Willebrand (vW) syndrome is a rare bleeding disorder which is frequently associated with immunological, malignant or cardiovascular disorders.
  • We report a patient with indolent small B-cell lymphoma (immunocytoma) and plasmacytic differentiation with an IgM kappa paraprotein who was admitted with retroperitoneal haematoma.
  • Acquired vW syndrome due to adsorption of vW factor on malignant cells was thus excluded.
  • In the multimeric analysis, all multimers were present similar to that in type 1 vW syndrome, but the triplet structures were blurred.
  • The patient required surgery and was successfully managed by chemotherapy consisting of rituximab and fludarabin as well as plasma exchange.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19572993.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Paraproteins; 0 / von Willebrand Factor
  •  go-up   go-down


63. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR, Waldenström's Macroglobulinemia Clinical Trials Group: Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol; 2005 Jan;16(1):132-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended rituximab therapy in Waldenström's macroglobulinemia.
  • BACKGROUND: Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic lymphoma.
  • Expression of the complement resistance antigens CD46, CD55 and CD59 was also evaluated on tumor cells pre- and post-therapy to determine impact on response.
  • RESULTS: Twenty-nine patients were enrolled and 26 patients completed the intended therapy.
  • Responses were observed in 18/24 (75%) patients with a serum IgM level of <6000 mg/dl, and only 1 of 5 (20%) patients with a level of >6000 mg/dl (P=0.03).
  • The median time to best response was 17 months, and only 2 of 19 responding patients progressed with a median follow-up of 29 months.
  • No differences in baseline expression of the complement resistance antigens CD46, CD55 and CD59 were observed among responding and non-responding patients, although post-therapy CD55 expression was higher in non-responding patients (P=0.002).
  • CONCLUSIONS: These data show that extended rituximab therapy is active and may lead to more major responses over standard dose rituximab in WM.
  • WM patients with serum IgM levels of <6000 mg/dl are more likely to benefit from extended rituximab therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598950.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23CA087977-03
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD46; 0 / Antigens, CD55; 0 / Antigens, CD59; 0 / Antineoplastic Agents; 0 / CD46 protein, human; 0 / Immunoglobulin M; 0 / Membrane Glycoproteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


64. Rieger K, Von Grünhagen U, Fietz T, Thiel E, Knauf W: Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed? Leuk Lymphoma; 2004 Feb;45(2):345-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
  • We report on the response rate and tolerability of Alemtuzumab (Campath-1H) in a series of heavily pretreated patients with B-CLL with a special focus on treatment-related problems.
  • Thirteen patients with B-chronic lymphocytic leukemia (B-CLL), 1 prolymphocytic leukemia (PLL), 1 mantle cell lymphoma (MCL) and 1 leukemic immunocytoma (IC) transformed into a high-grade NHL were included.
  • All patients received 3, 10 and 30 mg of Campath-1H on sequential days, and then were subsequently scheduled for 30 mg 3 times weekly.
  • Beginning with initiation of treatment recurrent profound leukopenia became evident in 13 out of 16 patients leading to treatment discontinuation.
  • Therefore, we developed a steroid co-medication regimen for the first 4 Campath-1H applications with quick tapering thereafter.
  • Infectious complications leading to treatment discontinuation consisted of pulmonary aspergillosis in one and bacterial pneumonia in another case.
  • In our series, application 3 times weekly was not possible due to hematotoxicity.
  • We recommend, therefore, flexible time intervals depending on the leukocyte counts.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antigens, CD / biosynthesis. Antigens, Neoplasm / biosynthesis. Female. Glycoproteins / biosynthesis. Humans. Male. Middle Aged. Remission Induction. Steroids / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101722.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Steroids; 3A189DH42V / alemtuzumab
  •  go-up   go-down


65. Sigal DS, Miller HJ, Schram ED, Saven A: Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood; 2010 Oct 21;116(16):2884-96
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Before the contemporary development of rationally designed antineoplastic therapies, cladribine was identified as a lymphocyte-specific agent.
  • Its profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and a median duration of response of nearly a decade after only a single 7-day course, is well known and revolutionized the treatment of hairy cell leukemia.
  • In a limited number of phase 3 trials and cross-study analyses, cladribine compared favorably with fludarabine, another purine nucleoside analog that is more commonly used in the treatment of indolent lymphoid malignancies.
  • Cladribine has been noted to have particular activity among lymphoid disorders with few effective therapies, specifically, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Hematologic Neoplasms / drug therapy
  • [MeSH-minor] Humans. Leukemia, Hairy Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Waldenstrom Macroglobulinemia / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20634380.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


66. Niitsu N, Kohri M, Hayama M, Nakamine H, Nakamura N, Bessho M, Higashihara M: Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Leuk Res; 2005 Nov;29(11):1361-4
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
  • A 71-year-old woman was referred to our hospital because of hyperproteinemia and serum M-protein (IgG-lambda type).
  • Since there were very few non-neoplastic plasma cells and small lymphocytes in addition to the absence of reactive lymph follicles and fibrosis, the patient was diagnosed as having plasmacytoma.
  • Treatment with melphalan/prednisolone resulted in considerable decrease in the serum IgG level and regression of the pulmonary tumors.
  • The effectiveness of the chemotherapy could confirm our diagnosis, although MALT-type lymphoma with plasmacytic differentiation cannot be completely ruled out.
  • [MeSH-major] Hypergammaglobulinemia / diagnosis. Lung Diseases / diagnosis. Lung Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878199.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Zinzani PL: Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol; 2002 Sep;15(3):505-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma: the evolving role of purine analogues.
  • Indolent non-Hodgkin's lymphoma is the commonest form of lymphoma in the USA and Europe, with a long natural history with multiple responses and relapses.
  • Indolent lymphomas include follicular lymphomas (the more frequent subtype), immunocytoma, and small lymphocytic lymphomas according to the Revised European-American Lymphoma classification.
  • The tendency has been to use simple oral medication until patients have more advanced aggressive disease but new agents such as the purine analogues have led to re-evaluation of this approach.
  • Within the last decade they have moved from salvage therapy to front-line studies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Purines / therapeutic use
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468402.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Purines
  • [Number-of-references] 70
  •  go-up   go-down


68. Zinzani PL, Magagnoli M, Bendandi M, Gherlinzoni F, Orcioni GF, Cellini C, Stefoni V, Pileri SA, Tura S: Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol; 2000 Mar;11(3):363-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously treated low-grade non-Hodgkin's lymphomas (LG-NHL).
  • The aim of this study was to define the therapeutic efficacy and toxicity of a combination of FLU and mitoxantrone (FN regimen) in untreated LG-NHL.
  • PATIENTS AND METHODS: We used a two-drug combination of FLU (25 mg/m2 i.v. on days 1 to 3) and mitoxantrone (10 mg/m2 i.v. on day 1) to treat 27 previously untreated patients with LG-NHL, Chemotherapy was repeated every four weeks for a total of six cycles.
  • Among 27 patients, 17 (63%) were diagnosed with follicular, 6 (22%) with small lymphocytic, and 4 (15%) with immunocytoma subtypes.
  • RESULTS: Of the 27 patients, 18 (67%) achieved complete response (CR) and 6 (22%) partial response, while the remaining 3 (11%) showed no benefit from the treatment.
  • Regarding histology, in the follicular subtype we observed an overall response rate of 94%, with a 76.5% CR rate.
  • CONCLUSIONS: These preliminary data show that the FN regimen is a very active, well-tolerated combination chemotherapy for untreated patients with advanced LG-NHL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811507.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


69. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J: Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma; 2002 Dec;3(3):163-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
  • Waldenström's macroglobulinemia is a low-grade lymphoplasmacytoid lymphoma characterized by CD20 expression on malignant cells.
  • Thus, we performed a prospective study in which 17 previously untreated patients with symptomatic macroglobulinemia were treated with rituximab 375 mg/m2 intravenously for 4 weeks.
  • Six patients (35%) achieved a partial response after extended treatment with rituximab.
  • Median time to response was 3 months.
  • The median time to progression (TTP) for all patients was 13 months.
  • One of 6 responding patients has progressed at 10 months, while the other 5 patients remain progression free with a follow-up range of > 22-40 months.
  • Treatment with rituximab was well tolerated and was not associated with myelosuppression; one third of the patients experienced infusion-related toxicity, usually fever and chills of mild degree.
  • Our prospective trial of extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia indicates that this agent is active, well tolerated, and might be associated with a long period without the need for further treatment.
  • Studies that will combine rituximab with chemotherapy or with other monoclonal antibodies might be of interest.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Clinical Trials as Topic. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Rituximab. Sex Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12521393.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


70. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol; 2009 Jan 10;27(2):250-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
  • PURPOSE: Nucleoside analogs (NAs) are considered as appropriate agents in the treatment of Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma.
  • Sporadic reports on increased incidence of transformation to high-grade non-Hodgkin's lymphoma and development of therapy-related myelodysplasia/acute leukemia (t-MDS/AML) among patients with WM treated with NAs prompted us to examine the incidence of such events in a large population of patients with WM.
  • PATIENTS AND METHODS: We examined the incidence of these events in 439 patients with WM, 193 and 136 of whom were previously treated with and without an NA, respectively, and 110 of whom had similar long-term follow-up without treatment.
  • RESULTS: Overall, 12 patients (6.2%) either developed transformation (n = 9; 4.7%) or developed t-MDS/AML (n = 3; 1.6%) among NA-treated patients, compared with one patient (0.4%) who developed transformation in the non-NA treated group (P < .001); no such events occurred among untreated patients.
  • Transformation and t-MDS/AML occurred at a median of 5 years from onset of NA therapy.
  • The median survival of NA-treated patients who developed transformation did not differ from other NA-treated patients as a result of effective salvage treatment used for transformed disease.
  • However, all NA-treated patients who developed t-MDS/AML died at a median of 5 months.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / pathology. Nucleosides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chlorambucil / therapeutic use. Cladribine / therapeutic use. Female. Follow-Up Studies. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


71. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM: Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res; 2009 Oct 1;15(19):6035-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
  • PURPOSE: Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma characterized by widespread involvement of the bone marrow.
  • Despite different options of therapy, Waldenstrom macroglobulinemia is still incurable.
  • We sought to determine whether the protein tyrosine kinase Src regulates adhesion, migration, and survival in Waldenstrom macroglobulinemia.
  • EXPERIMENTAL DESIGN: We tested the expression of Src tyrosine kinase in Waldenstrom macroglobulinemia and normal cells, and the effect of the specific Src inhibitor AZD0530 on the adhesion, migration, cell cycle, and survival of a Waldenstrom macroglobulinemia cell line and patient samples.
  • Moreover, we tested the effect of AZD0530 on cytoskeletal and cell cycle signaling in Waldenstrom macroglobulinemia.
  • RESULTS: We show that Src is overexpressed in Waldenstrom macroglobulinemia cells compared with control B cells, and that the use of the Src inhibitor AZD0530 led to significant inhibition of adhesion, migration, and cytoskeletal signaling induced by SDF1.
  • Moreover, inhibition of Src activity induced G(1) cell cycle arrest; however, it had minimal effect on survival of Waldenstrom macroglobulinemia cells, and no significant effect on survival of normal cells.
  • CONCLUSIONS: Taken together, these results delineate the role of Src kinase activity in Waldenstrom macroglobulinemia and provide the framework for future clinical trials using Src inhibitors in combination with other drugs to improve the outcome of patients with Waldenstrom macroglobulinemia.

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Mar 26;20(13):1601-6 [11313907.001]
  • [Cites] Blood. 2008 May 15;111(10):5068-77 [18334673.001]
  • [Cites] Lancet Oncol. 2003 Nov;4(11):679-85 [14602248.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):306-7 [18477987.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):469-71 [18538730.001]
  • [Cites] Blood. 2008 Jul 1;112(1):150-8 [18448868.001]
  • [Cites] BJU Int. 2009 Feb;103(4):434-40 [19154462.001]
  • [Cites] J Thorac Oncol. 2009 Apr;4(4):448-54 [19240653.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203 [19293266.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):209-14 [15380511.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):7906-9 [15489908.001]
  • [Cites] Oncogene. 2004 Oct 18;23(48):8001-6 [15489917.001]
  • [Cites] Adv Cancer Res. 1999;76:61-119 [10218099.001]
  • [Cites] Curr Pharm Des. 2005;11(9):1119-30 [15853660.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1398-401 [16533761.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jun;97(3):263-74 [16333527.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1918-29 [16986126.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):91-100 [17150037.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2708-17 [17119115.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5096-103 [17303694.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1366-75 [17761288.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7232-6 [18094400.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):56-65 [17905674.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99 [18389098.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Apr;8(3):342-9 [18393792.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):107-9 [12720117.001]
  • (PMID = 19755386.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA125690; United States / NCI NIH HHS / CA / R21CA126119-01; United States / NCI NIH HHS / CA / R21 CA126119-01A1; United States / NCI NIH HHS / CA / R01CA125690-01; United States / NCI NIH HHS / CA / R21 CA126119
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzodioxoles; 0 / Chemokine CXCL12; 0 / Cytotoxins; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / Oncogene Protein pp60(v-src)
  • [Other-IDs] NLM/ NIHMS133060; NLM/ PMC2990685
  •  go-up   go-down


72. Machet L, De Muret A, Wiezberka E, Bernez A, Abdallah-Lotf M, Linassier C, Petrella T: [Agranular CD4+ CD56+ CD123+ hematodermic neoplasm (blastic NK-cell lymphoma) revealed by cutaneous localization: 2 cases]. Ann Dermatol Venereol; 2004 Nov;131(11):969-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Agranular CD4+ CD56+ CD123+ hematodermic neoplasm (blastic NK-cell lymphoma) revealed by cutaneous localization: 2 cases].
  • BACKGROUND: Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) has been recently described.
  • Preliminary histological examination of cutaneous biopsy taken in both patients showed a malignant proliferation suggesting a cutaneous lymphoma, and the patients were referred.
  • The first patient was treated with chemotherapy, with complete remission.
  • The patient died one year after the diagnosis of the disease, in spite of intensification of the treatment.
  • Treatment is still ongoing in the second patient.
  • Some cases have been published under the "term of blastic NK lymphoma" which is the actual term for the disease in the WHO classification.
  • However, the tumor cells derive from the dendritic plasmacytoid cells, also called type 2 dendritic cells, and perhaps from a common precursor to lymphocyte T and dendritic plasmacytoid cells.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / analysis. Killer Cells, Natural. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Receptors, Interleukin-3 / analysis. Skin Neoplasms / immunology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Interleukin-3 Receptor alpha Subunit. Male. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602384.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / IL3RA protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / Receptors, Interleukin-3
  •  go-up   go-down


73. Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol; 2000 Feb;18(4):773-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
  • In-depth analysis of the CR rate with respect to histologic type showed that FLU seemed to be superior to FLU-ID in treating follicular lymphomas (60% v 40%, respectively), whereas FLU-ID seemed to be more effective than FLU in treating nonfollicular lymphomas (small lymphocytic, 43% v 29%, respectively; immunocytoma, 38% v 23%, respectively; P = not significant), excluding the mantle-cell subset (in which there was no difference between the two groups).
  • However, with a median follow-up of 19 months, only 29 patients (62%) who received FLU alone have maintained their initial CR, compared with 32 (84%) of those who received FLU-ID therapy (P =.021).
  • CONCLUSION: Although the FLU-ID regimen may not significantly improve the induction of CR in most indolent-lymphoma patients, our preliminary data do suggest that, with respect to FLU alone, it may be capable of conferring a longer-lasting CR and that it might be superior in terms of CR rate in small lymphocytic and immunocytoma subtypes.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage. Lymphoma, Mantle-Cell / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Disease Progression. Female. Follow-Up Studies. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Linear Models. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10673518.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


74. Khoor A, Myers JL, Tazelaar HD, Kurtin PJ: Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol; 2004 Feb;121(2):200-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient 1 (aged 62 years) had multiple pulmonary nodules and underwent 2 separate lung biopsies, the first showing nodules composed of kappa light-chain deposits accompanied by low-grade lymphoplasmacytic lymphoma limited to the lung and the second, obtained after chemotherapy 9 months later, showing only residual nodules without persistent lymphoma.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14983932.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


75. Metzgeroth G, Sick Ch, Maywald O, Schatz M, Kuhn Ch, Hehlmann R, Hastka J: Multilobated nuclei in Waldenström' macroglobulinaemia. Eur J Haematol; 2003 Oct;71(4):307-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of Waldenström' macroglobulinaemia, where the bone marrow analysis showed an almost complete infiltration by a heterogeneous population, consisting of 80% small lymphoplasmacytoid cells and 20% large atypical cells with multilobulated nuclei.
  • Fluorescence in situ hybridization analysis with a chromosome 8 painting probe on interphase nuclei revealed only two signals in each cell, including in those with multiple nuclei.
  • In contrast to the published multiple myeloma cases, our patient showed good response to chemotherapy.
  • After successful chemotherapy, the morphology of the lymphoma changed into typical lymphoplasmacytoid lymphoma.
  • Five years after the initial diagnosis, the patient is still alive and in good health.
  • [MeSH-major] Cell Nucleus / metabolism. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] ADP-ribosyl Cyclase / biosynthesis. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD38. Bone Marrow Cells / cytology. Chromosomes, Human, Pair 8 / genetics. Diploidy. Humans. Immunoglobulin M / immunology. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Male. Membrane Glycoproteins. Middle Aged. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950243.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Immunoglobulin M; 0 / Membrane Glycoproteins; EC 3.2.2.5 / ADP-ribosyl Cyclase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


76. Arcari A, Anselmi E, Bernuzzi P, Bertè R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, Cavanna L: Primary pancreatic lymphoma. Report of five cases. Haematologica; 2005 Feb;90(2):ECR09
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma. Report of five cases.
  • Primary pancreatic lymphoma (PPL) is a very rare disease.
  • None of these patients had evidence of extrapancreatic disease and they were categorized as PPL involving pancreas only (stage IE, 3 patients) or pancreas and peripancreatic lymph nodes (stage IIE, 2 patients).
  • The histological diagnosis (3 diffuse-large cell non-Hodgkin's lymphoma and 2 lymphoplasmacytic lymphoma/immunocytoma) was made by ultrasound-guided fine needle aspiration biopsy and tissue core fine-needle biopsy in three patients and by surgery in the remaining two patients.
  • The three patients diagnosed by percutaneous biopsy were treated with chemotherapy as front-line therapy and two of them received also local radiotherapy; one of these patients is still alive in complete remission at 69 months, one died of an unrelated disease at 67 months and one died of lymphoma relapse at 88 months.
  • Two patients underwent pancreaticoduodenectomy plus adjuvant chemotherapy; one of them died of recurrent cholangitis 8 months after surgery while the other one is still alive in complete remission after 160 months.
  • 2) histological diagnosis can be easily obtained by percutaneous US-guided tissue core biopsy;.
  • 3) surgery can be avoided both for diagnosis and therapy but the treatment of choice of PPL may only be evaluated on a larger series of patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy. Biopsy, Needle. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713583.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


77. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood; 2010 Apr 01;115(13):2578-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  • Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals.
  • In in vivo analyses of B-cell lymphoma cell lines and primary tumors, Syk inhibition induces apoptosis.
  • These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin lymphoma (B-NHL).
  • (1) diffuse large B-cell lymphoma (DLBCL), (2) follicular lymphoma (FL), and (3) other NHL, including mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasmacytic lymphomas, and small lymphocytic leukemia/chronic lymphocytic leukemia (SLL/CLL).
  • Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Oxazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Diarrhea / chemically induced. Disease-Free Survival. Female. Hematologic Diseases / chemically induced. Humans. Hypertension / chemically induced. Male. Middle Aged. Salvage Therapy. Syk Kinase. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Feb 15;356(7):741-2 [17301308.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2093-101 [17051243.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77 [17490694.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2230-7 [18006696.001]
  • [Cites] Blood. 2008 Aug 1;112(3):782-92 [18487510.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Arthritis Rheum. 2008 Nov;58(11):3309-18 [18975322.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):549-62 [19017179.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6 [19107952.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2508-16 [18981293.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3050-8 [19074730.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6153-60 [19369227.001]
  • [Cites] Blood. 2009 Jul 16;114(3):638-46 [19387007.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1029-37 [19491390.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3822-9 [19581539.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):148-54 [10689303.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1300-6 [10903730.001]
  • [Cites] Science. 2002 May 31;296(5573):1641-2 [12040177.001]
  • [Cites] J Allergy Clin Immunol. 2002 Sep;110(3):366-73 [12209081.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1057-69 [12453414.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Cell. 2004 Jun 11;117(6):787-800 [15186779.001]
  • [Cites] Mol Cell. 2004 Jun 18;14(6):696-7 [15200948.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1073-83 [9323135.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):143-51 [10322153.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):283-94 [16557260.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5715-9 [16670274.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3135-42 [16835385.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3428-33 [16888096.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008 [16946104.001]
  • [CommentIn] Blood. 2010 Apr 1;115(13):2561-2 [20360472.001]
  • (PMID = 19965662.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00446095
  • [Grant] United States / NCI NIH HHS / CA / P50 CA130805; United States / NCI NIH HHS / CA / CA-130805
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Oxazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / SYK protein, human; EC 2.7.10.2 / Syk Kinase; SQ8A3S5101 / fostamatinib
  • [Other-IDs] NLM/ PMC2852362
  •  go-up   go-down


78. Löffler H, Kosely F, Ho AD, Krämer A: [Blastic plasmacytoid dendritic cell neoplasm - a rare differential diagnosis of neoplastic skin infiltrations associated with systemic symptoms]. Dtsch Med Wochenschr; 2009 Sep;134(39):1927-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blastic plasmacytoid dendritic cell neoplasm - a rare differential diagnosis of neoplastic skin infiltrations associated with systemic symptoms].
  • [Transliterated title] Blastische plasmozytoide Neoplasie dendritischer Zellen - seltene Differenzialdiagnose neoplastischer Hautinfiltrate mit systemischer Beteiligung.
  • HISTORY AND CLINICAL FINDINGS: A 70-year-old female patient developed a non-pruritic, indolent rash associated with infections and peripheral blood abnormalities.
  • A skin biopsy was suggestive of malignant lymphoma of the skin.
  • DIAGNOSIS: Blastic plasmacytoid dendritic cell neoplasm (formerly known as blastic NK cell lymphoma).
  • TREATMENT AND COURSE: After the first course of induction chemotherapy with daunorubicin and cytarabin, both the rash and the hematologic findings of bone marrow and peripheral blood showed a complete remission.
  • CONCLUSION: The blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive hematopoietic neoplasm most likely related to acute myeloid leukemia (AML).
  • Since cutaneous involvement is regularly present at diagnosis, the differential diagnosis of unexplained skin lesions should include this disease entity, especially if peripheral blood abnormalities are present.
  • Despite the initial response to cytostatic therapy being mostly excellent, the prognosis is poor.
  • Hence, treatment as high-risk AML seems advisable.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Exanthema. Female. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Pancytopenia. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Blastic Plasmacytoid Dendritic Cell.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19760552.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


79. Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF: Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clin Lymphoma; 2005 Mar;5(4):294-7
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
  • The WM1 study is a prospective randomized open-label study that includes patients with previously untreated Waldenstrom's macroglobulinemia (WM), splenic lymphoma with villous lymphocytes (SLVL), and nonimmunoglobulin (Ig) M lymphoplasmacytic lymphoma (LPL) who have an indication for treatment.
  • Primary endpoints are response to therapy and duration of response; secondary endpoints are improvement in hematologic parameters, toxicity of therapy, quality of life, and survival.
  • To detect a difference in response rate of patients with WM of 15%, assuming that the overall response rates will be 50% to chlorambucil and 65% to fludarabine, with a power of 80%, requires the sample size of each group to be 183, indicating the need for collaboration among a number of national investigator groups.
  • Registration, randomization, and data collection are entirely Internet-based (www.waldenstroms.org), and the study is organized by an international collaboration, with a planned interim analysis and an external data monitoring committee.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / therapeutic use. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794869.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


80. Jacob MC, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, Béné MC, Bensa JC, Brière F, Plumas J: CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica; 2003 Aug;88(8):941-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells.
  • BACKGROUND AND OBJECTIVES: The CD4+ CD56+ lin- immunophenotype characterizes rare malignancies, so far considered as arising from the transformation of NK progenitors, and therefore classified as blastic NK-cell leukemia/lymphoma by the WHO committee.
  • Recently it was formally demonstrated that such malignancies do, in fact, develop from plasmacytoid dendritic cells (pDC), according to immunophenotypic and functional criteria.
  • The clinico-biological features of this neoplasm were moreover recently summarized from a large series of 23 patients.
  • Most patients were initially sensitive to chemotherapy regimens, but they rapidly relapsed and died within 3 years.
  • STATE OF THE ART AND PERSPECTIVES: The concordant characteristics led us to confirm that this neoplasm actually represents a new entity, that we propose to rename early pDC leukemia/lymphoma.
  • The diagnosis is primarily based on a characteristic immunophenotypic profile i.e.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12935983.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  •  go-up   go-down


81. Yap LM, Blum R, Foley P, McCormack C, Turner H, Seymour JF, Prince HM: Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications. Australas J Dermatol; 2003 May;44(2):110-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications.
  • Primary cutaneous B-cell lymphoma (PCBCL) is rare, with few series reported in the literature.
  • Its classification and treatment remain controversial.
  • Biopsy specimens of 13 patients with PCBCL were classified according to both the European Organization for Research and Treatment of Cancer (EORTC) and the new World Health Organization (WHO) classifications.
  • Treatment and clinical outcomes were documented.
  • Using the EORTC classification there were seven men and six women aged 32-85 years (mean = 51 years) with follicle centre cell (FCC) lymphoma (nine), immunocytoma (two) and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg) (two).
  • When the WHO classification was used, the nine patients with FCC were reclassified as follicle centre (five) and diffuse large B-cell lymphoma (four).
  • Initial treatment consisted of radiotherapy alone (seven), combination chemotherapy alone (one), combined chemoradiotherapy (three) and surgery (two).
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / therapy. Skin Neoplasms / classification. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy. Europe. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Prospective Studies. Radiotherapy / methods. Rare Diseases. Registries. Risk Assessment. Surgical Procedures, Operative / methods. Survival Rate. Treatment Outcome. World Health Organization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12752183.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


82. Ho AD, Hensel M: Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol; 2006 Apr;43(2 Suppl 2):S2-10
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pentostatin for the treatment of indolent lymphoproliferative disorders.
  • ADA is present in all human tissues, with the highest levels in the lymphoid system.
  • Through the efforts of a few investigators, low-dose regimens that are active and well tolerated for indolent lymphoid malignancies have been developed.
  • Lymphoplasmacytic lymphoma (LL) is an indolent chronic B-cell lymphoproliferative disorder moderately responsive to alkylating agents.
  • This is of significance for patients who might benefit from high-dose chemotherapy with autologous stem cell transplantation.
  • [MeSH-major] Lymphoproliferative Disorders / drug therapy. Pentostatin / therapeutic use
  • [MeSH-minor] Adenosine Deaminase Inhibitors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549110.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenosine Deaminase Inhibitors; 395575MZO7 / Pentostatin
  • [Number-of-references] 92
  •  go-up   go-down


83. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • Abnormal plasmacytoid cells were seen in both the peripheral blood (PB) and the bone marrow (BM).
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • A histologic examination of the gastric mucosa showed a diffuse infiltration of small- to medium-sized lymphoid CD20-bearing cells, some of which showed a plasmacytoid morphology.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The PE contained numerous lymphoid cells with plasmacytoid morphology that Southern blotting analysis showed to have a monoclonal IgH gene rearrangement pattern.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • In general, gastric MALT lymphoma cells have a tendency to differentiate into plasma cells.
  • In this article, we show that the cell character of API-2/MLT-positive MALT lymphoma is preserved even when the cells are disseminated.
  • This is the first published case, to our knowledge, in which two differentiation stages of MALT lymphoma cells infiltrating into PE have been confirmed by flow cytometric analysis.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Oncogene Proteins, Fusion / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


84. Li BZ, Yu CJ, Xu JJ, Lu HF, Shi DR: [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Aug;44(8):651-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics and chromosomal abnormalities in salivary mucosa associated lymphoid tissue lymphomas].
  • OBJECTIVE: To study the morphological and genetic characteristics in salivary gland marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) lymphomas.
  • Except surgical resection, patients did not get systematic radio-or chemotherapy.
  • Eight to fifteen months after operation, 8 cases found recurred nodules on the original resected sites or cervical lymph nodes, but did not get repeated biopsy.
  • All follow-up time was from 23 to 54 months.
  • The final diagnosis depends on the pathological findings, the number and distribution of monocytoid B cells and clusters of plasmacytoid cells are hints for diagnosis of salivary MALT lymphomas, invasion of blood vessels or nerve also help for malignant diagnosis. t(11;18) and trisomy 18 may be the main chromosomal abnormalities in salivary gland MALT lymphomas, but with low morbidity.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961773.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement